EP2180046A1 - Procédé de production d'acides gras à longues chaînes multi-insaturés dans des organismes transgéniques - Google Patents

Procédé de production d'acides gras à longues chaînes multi-insaturés dans des organismes transgéniques Download PDF

Info

Publication number
EP2180046A1
EP2180046A1 EP09179432A EP09179432A EP2180046A1 EP 2180046 A1 EP2180046 A1 EP 2180046A1 EP 09179432 A EP09179432 A EP 09179432A EP 09179432 A EP09179432 A EP 09179432A EP 2180046 A1 EP2180046 A1 EP 2180046A1
Authority
EP
European Patent Office
Prior art keywords
seq
nucleic acid
acyl
fatty acids
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09179432A
Other languages
German (de)
English (en)
Other versions
EP2180046B1 (fr
Inventor
Petra Cirpus
Amine Abbadi
Jelena Kirsch
Jörg BAUER
Ernst Heinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Plant Science GmbH
Original Assignee
BASF Plant Science GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF Plant Science GmbH filed Critical BASF Plant Science GmbH
Publication of EP2180046A1 publication Critical patent/EP2180046A1/fr
Application granted granted Critical
Publication of EP2180046B1 publication Critical patent/EP2180046B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)

Definitions

  • the present invention relates to a process for producing polyunsaturated fatty acids in an organism by introducing into the organism nucleic acids encoding polypeptides having acyl-CoA: lysophospholipid acyltransferase activity.
  • these nucleic acid sequences may optionally be expressed in the transgenic organism together with other nucleic acid sequences encoding polypeptides of the fatty acid or lipid metabolism.
  • the invention furthermore relates to the nucleic acid sequences according to the invention, nucleic acid constructs containing the nucleic acid sequences according to the invention, vectors comprising the nucleic acid sequences according to the invention and / or the nucleic acid constructs and transgenic organisms containing the aforementioned nucleic acid sequences, nucleic acid constructs and / or vectors.
  • Another part of the invention relates to oils, lipids and / or fatty acids prepared by the process according to the invention and their use.
  • Fatty acids and triglycerides find a variety of applications in the food industry, animal nutrition, cosmetics and pharmaceuticals. Depending on whether it is free saturated or unsaturated fatty acids or around Triglycerides with an increased content of saturated or unsaturated fatty acids, they are suitable for a variety of applications, such as polyunsaturated fatty acids are added to the baby food to increase nutritional value.
  • Polyunsaturated ⁇ -3 and ⁇ -6 fatty acids represent an important component of animal and human food. Due to the usual composition of human food today is an addition of polyunsaturated ⁇ -3 fatty acids, which occur mainly in fish oils Especially important to food.
  • DHA docosahexaenoic acid
  • the polyunsaturated ⁇ -3 fatty acids are also considered to have a positive effect on the blood cholesterol level and thus on the possibility of preventing heart disease.
  • ⁇ -3 fatty acids By adding these ⁇ -3 fatty acids to the diet, the risk of heart disease, stroke or hypertension can be significantly reduced.
  • inflammatory, especially chronic inflammatory processes in the context of immunological diseases such as rheumatoid arthritis can be positively influenced by ⁇ -3 fatty acids. They are therefore added to foods, especially dietary foods, or are used in medicines.
  • ⁇ -6 fatty acids such as arachidonic acid tend to have a negative effect on these diseases in these rheumatic diseases due to our usual food composition.
  • ⁇ -3 and ⁇ -6 fatty acids are precursors of tissue hormones, the so-called eicosanoids such as the prostaglandins derived from dihomo- ⁇ -linolenic acid, arachidonic acid and eicosapentaenoic acid, and the thromboxanes and leukotrienes derived from arachidonic acid and eicosapentaenoic acid.
  • Eicosanoids which are formed from ⁇ -6 fatty acids (so-called PG 2 series), promote in the Usually inflammatory reactions, while eicosanoids from ⁇ -3 fatty acids (so-called PG 3 series) have little or no pro-inflammatory effect.
  • the free fatty acids are advantageously prepared by saponification.
  • Common natural sources of these fatty acids are fish such as herring, salmon, sardine, perch, eel, carp, trout, halibut, mackerel, zander or tuna, and algae.
  • ⁇ -6-desaturases are in WO 93/06712 . US 5,614,393 .
  • WO 96/21022 WO00 / 21557 and WO 99/27111 during their use for the production of fatty acids in transgenic organisms in WO98 / 46763 .
  • WO98 / 46764 and WO98 / 46765 is described.
  • microorganisms for the production of PUFAs are microorganisms such as Thraustochytrien or Schizochytrien strains, algae such as Phaeodactylum tricornutum or Crypthecodinium species, ciliates such as Stylonychia or Codpidium and fungi such as Mortierella, Entomophthora or Mucor.
  • Thraustochytrien or Schizochytrien strains such as Phaeodactylum tricornutum or Crypthecodinium species
  • ciliates such as Stylonychia or Codpidium
  • fungi such as Mortierella, Entomophthora or Mucor.
  • mutation and selection of strains with improved production of a particular molecule, such as polyunsaturated fatty acids is a time-consuming and difficult procedure. Therefore, whenever possible, genetic engineering methods are preferred as described above.
  • microorganisms can be However, only limited amounts of the desired polyunsaturated fatty acids such as DPA, EPA or ARA produce, which usually also incurred depending on the microorganism used as fatty acid mixtures of, for example, EPA, DPA and DHA.
  • PUFAs large scale production of fine chemicals can be advantageously carried out in plants engineered to produce the aforementioned PUFAs.
  • Particularly suitable plants for this purpose are oil crops containing high levels of lipid compounds, such as rapeseed, canola, linseed, soy, sunflower, borage and evening primrose.
  • other crops containing oils or lipids and fatty acids are also well-suited, as mentioned in the detailed description of this invention.
  • a number of mutant plants have been developed which produce a spectrum of desirable lipids and fatty acids, cofactors and enzymes.
  • microalgae such as Phaeodactylum and mosses
  • Physcomitrella unsaturated fatty acids such as linoleic acid or linolenic acid in the form of their acyl-CoAs in several desaturation and Elongationsön to LCPUFAs ( Zank et al. (2000) Biochemical Society Transactions 28: 654-658 ).
  • biosynthesis of DHA involves chain shortening via ⁇ -oxidation in addition to desaturation and elongation steps.
  • LCPUFAs exist in microorganisms and lower plants either exclusively in the form of membrane lipids, as in Physcomitrella and Phaeodactylum, or they are present in both membrane lipids and in triacylglycerides, as in Schizochytrium and Mortierella.
  • the incorporation of LCPUFAs into lipids and oils is catalyzed by various acyltransferases and transacylases already known for the incorporation of saturated and unsaturated fatty acids ( Slabas (2001) J. Plant Physiology 158: 505-513 ; Frentzen (1998) fat / lipid 100: 161-166 ; Cases et al. (1998) Proc. Nat. Acad. Sci.
  • the acyltransferases are enzymes of the so-called Kennedy pathway located on the cytoplasmic side of the endoplasmic reticulum membrane system, hereafter referred to as 'ER'.
  • 'ER' cytoplasmic side of the endoplasmic reticulum membrane system
  • membranes of the ER can be considered as so-called 'microsomal fractions' are isolated from different organisms ( Knutzon et al. (1995) Plant Physiology 109: 999-1006 ; Mishra & Kamisaka (2001) Biochemistry 355: 315-322 ; US 5968791 ).
  • These ER-linked acyltransferases in the microsomal fraction use acyl-CoA as the activated form of the fatty acids.
  • Glycerol-3-phosphate acyltransferase catalyzes the incorporation of acyl groups at the sn-1 position of glycerol-3-phosphate.
  • 1-Acylglycerol-3-phosphate acyltransferase (EC 2.3.1.51), also called lysophosphatidic acid acyltransferase, hereafter LPAAT, catalyzes the incorporation of acyl groups at the sn-2 position of lysophosphatidic acid, hereinafter abbreviated as LPA.
  • DAGAT diacylglycerol acyltransferase
  • PDAT phospholipid diacylglycerol acyltransferase
  • LPCAT lysophosphatidylcholine acyltransferase
  • LPCAT The enzymatic activity of a LPCAT was first described in rats ( Land (1960) J. Biol. Chem. 235: 2233-2237 ). In plants there exists a plastid isoform of LPCAT ( Akermoun et al. (2000) Biochemical Society Transactions 28: 713-715 ) as well as an ER-bound isoform ( Tumaney and Rajasekharan (1999) Biochimica et Biophysica Acta 1439: 47-56 ; Fraser and Stobart, Biochemical Society Transactions (2000) 28: 715-7718 ).
  • LPCATs are involved in the biosynthesis and transacylation of polyunsaturated fatty acids in both animals and plants ( Stymne and Stobart (1984) Biochem. J. 223: 305-314 ; Stymne and Stobart (1987) in 'The Biochemistry of Plants: a Comprehensive Treatise', Vol. 9 (Stumpf, PK ed.) Pp. 175-214, Academic Press, New York ).
  • linoleic acid C18: 2 and linolenic acid (C18: 3).
  • ARA Arachidonic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • genes encoding enzymes of the biosynthesis of LCPUFAs in oilseeds are advantageously introduced and expressed via genetic engineering methods. These are, for example, genes encoding a ⁇ 6-desaturase, ⁇ 6-elongase, ⁇ 5-desaturase, ⁇ 5-elongases and ⁇ 4-desaturase.
  • ⁇ 6-desaturase genes from the moss Physcomitrella patens and ⁇ 6 elongase genes from P. patens and the nematode C. elegans have already been isolated.
  • the polyunsaturated fatty acids prepared in the process according to the invention contain at least two, advantageously three double bonds. Particularly advantageously, the fatty acids contain four or five double bonds.
  • Fatty acids produced in the process advantageously have 16, 18, 20 or 22 C atoms in the fatty acid chain. These fatty acids can be produced as the only product in the process or in a fatty acid mixture.
  • nucleic acid sequences used in the method of the invention are isolated nucleic acid sequences encoding polypeptides having acyl-CoA: lysophospholipid acyltransferase activity.
  • the polyunsaturated fatty acids produced in the process are advantageously bound in membrane lipids and / or triacylglycerides, but may also be present as free fatty acids or bound in the form of other fatty acid esters in the organisms. As stated, they may be present as "pure products" or else advantageously in the form of mixtures of different fatty acids or mixtures of different glycerides.
  • the different fatty acids bound in the triacylglycerides can be derived from short-chain fatty acids having 4 to 6 C atoms, medium-chain fatty acids having 8 to 12 C atoms or long-chain fatty acids having 14 to 24 C atoms; preference is given to long-chain fatty acids the long-chain C 18 , C 20 and / or C 22 fatty acids (LCPUFAs).
  • fatty acid esters with polyunsaturated C 16 , C 18 , C 20 and / or C 22 fatty acid molecules having at least two double bonds in the fatty acid ester.
  • the fatty acid esters with polyunsaturated C 16 , C 18 , C 20 and / or C 22 fatty acid molecules can be prepared from the organisms used for the preparation of the fatty acid esters in the form of an oil or lipid, for example in the form of compounds such as Sphingolipids, phosphoglycerides, lipids, glycolipids such as glycosphingolipid, phospholipids such as phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol or diphosphatidylglycerol, monoacylglycerides, diacylglycerides, triacylglycerides or other fatty acid esters such as the acetyl-coenzymeA esters containing at least two polyunsaturated fatty acids three, containing double bonds, can be isolated.
  • compounds such as Sphingolipids, phosphoglycerides,
  • the polyunsaturated fatty acids are also present as free fatty acids or bound in other compounds in the organisms, advantageously the plants.
  • the various compounds mentioned above are present in the organisms in an approximate distribution of 80 to 90% by weight of triglycerides, 2 to 5% by weight of diglycerides, 5 to 10% by weight of monoglycerides, 1 to 5 wt .-% of free fatty acids, 2 to 8 wt .-% phospholipids ago, wherein the sum of the various compounds to 100 wt .-% complements.
  • the LCPUFAs produced are present in a content of at least 3% by weight, advantageously at least 5% by weight, preferably at least 8% by weight, more preferably at least 10% by weight, most preferably at least 15% by weight, based on the total fatty acids in the transgenic organisms, advantageously a transgenic plant.
  • linoleic acid C 18: 2 or linolenic acid (C 18: 3) are passed through several reaction steps, the end products of the process such as arachidonic acid (ARA) or eicosapentaenoic acid (EPA) not as absolute pure products, but there are always small traces of the precursors in the final product included.
  • ARA arachidonic acid
  • EPA eicosapentaenoic acid
  • the precursors should advantageously not more than 20 wt .-%, preferably not more than 15 wt .-%, more preferably not more than 10 wt .-%, most preferably not more than 5, 4, 3, 2, 1 wt .-%, based on the amount of the respective end product.
  • ARA or only EPA are bound in the process of the invention or produced as free fatty acids in a transgenic plant as end products. If both compounds (ARA + EPA) are prepared simultaneously, they are advantageously prepared in a ratio of at least 1: 2 (EPA: ARA), preferably of at least 1: 3, preferably of at least 1: 4, more preferably of at least 1: 5 ,
  • chemically pure polyunsaturated fatty acids or fatty acid compositions can be prepared by the methods described above.
  • the fatty acids or fatty acid compositions from the organism such as the microorganisms or plants or the culture medium in which or on which the organisms were grown, or from the organism and the culture medium in a known manner, for example via extraction, distillation, crystallization, chromatography or Isolated combinations of these methods.
  • These chemically pure fatty acids or fatty acid compositions are advantageous for applications in the food industry, the cosmetics industry and especially the pharmaceutical industry.
  • organisms such as fungi such as Mortierella or Traustochytrium, yeasts such as Saccharomyces or Schizosaccharomyces, mosses such as Physcomitrella or Ceratodon, non-human animals such as Caenorhabditis, algae such as Crypthecodinium or Phaeodactylum or plants such as dicotyledonous or monocotyledonous plants come as organism for the preparation in the process according to the invention in question.
  • fungi such as Mortierella or Traustochytrium
  • yeasts such as Saccharomyces or Schizosaccharomyces
  • mosses such as Physcomitrella or Ceratodon
  • non-human animals such as Caenorhabditis
  • algae such as Crypthecodinium or Phaeodactylum
  • plants such as dicotyledonous or monocotyledonous plants come as organism for the preparation in the process according to the invention in question.
  • organisms which belong to the oil-producing organisms, that is, which are used for the production of oils, such as mushrooms such as Mortierella or Traustochytrium, algae such as Crypthecodinium or Phaeodactylum or plants, especially oil crops containing high levels of lipid compounds such as peanut, canola, canola, sunflower, safflower (safflower), poppy, mustard, hemp, castor, olive, sesame, calendula, punica, Evening Primrose, Mullein, Thistle, Wild Rose, Hazelnut, Almond, Macadamia, avocado, Bay Leaf, Pumpkin, Linseed, Soya, Pistachios, Borage, Trees (Oil Palm, Coconut or Walnut) or Crops such as Corn, Wheat, Rye, Oats, Triticale, Rice , Barley, cotton, cassava, pepper, tagetes, solanaceae plants such as potato, tobacco, aubergine and tomato
  • oils such as mushrooms such as Mortierella or
  • Preferred plants according to the invention are oil crop plants, such as peanut, oilseed rape, canola, sunflower, safflower, poppy, mustard, hemp, castor, olive, calendula, punica, evening primrose, pumpkin, flax, soy, borage, trees (oil palm, coconut) , Particularly preferred are C18: 2 and / or C18: 3 fatty acid-rich plants such as sunflower, safflower, tobacco, mullein, sesame, cotton, pumpkin, poppy, evening primrose, walnut, flax, hemp, thistle or safflower. Most preferred are plants such as safflower, sunflower, poppy, evening primrose, walnut, flax or hemp.
  • nucleic acids introduced under method step (a) it is advantageous, in addition to the nucleic acids introduced under method step (a), to introduce further nucleic acids into the organism which code for enzymes of the fatty acid or lipid metabolism.
  • genes of the fatty acid or lipid metabolism can advantageously be used in combination with the inventive acyl-CoA: lysophospholipid acyltransferase in the process for producing polyunsaturated fatty acids; genes of the fatty acid or lipid metabolism are advantageously selected from the group consisting of acyl-CoA Dehydrogenase (s), acyl-carrier protein-desaturase (s), acyl-ACP-thioesterase (s), fatty acid acyltransferase (s), fatty acid synthase (s), fatty acid hydroxylase ( n), acetyl coenzyme A carboxylase (s), Acyl coenzyme A oxidase (s), fatty acid desaturase (s), fatty acid acetylenases, lipoxygenases, triacylglycerol lipases, allene oxide synthases, hydroperoxide lyases or fatty acid elongase (s)
  • nucleic acids used in the method according to the invention which code for polypeptides having acyl-CoA: lysophospholipid acyltransferase activity, advantageously in combination with nucleic acid sequences which are suitable for polypeptides of fatty acid or lipid metabolism with ⁇ -4-, ⁇ -5, ⁇ Encode ⁇ 6- ⁇ , ⁇ -8-desaturase or ⁇ -5, ⁇ -6 or ⁇ -9-Elongasecrettician, a variety of polyunsaturated fatty acids can be prepared in the process according to the invention.
  • fatty acids derived from C18: 2 fatty acids such as GLA, DGLA or ARA or those derived from C18: 3 Derive fatty acids, such as SDA, ETA or EPA.
  • linoleic acid LA, C18: 2 ⁇ 9,12
  • GLA, DGLA and ARA can arise as products of the process, which may be present as free fatty acids or bound.
  • ⁇ -linolenic acid ALA, C18: 3 ⁇ 9,12,15
  • SDA, ETA can be used as products of the process and EPA arise which may be present as free fatty acids or bound as described above.
  • lysophospholipid acyltransferase advantageous in combination with the ⁇ -5 and ⁇ -6-desaturase and the ⁇ -6 elongase, or the ⁇ -5 and ⁇ -8 Desaturase and the ⁇ -9 elongase or in combination with only the first two genes of the synthesis chain, ⁇ -6-desaturase and ⁇ -6 elongase or ⁇ -8-desaturase and ⁇ -9 elongase, can be in the aforementioned Organisms, advantageously in the aforementioned plants, selectively produce only individual products.
  • ⁇ -6-desaturase and ⁇ -6 elongase Due to the activity of ⁇ -6-desaturase and ⁇ -6 elongase, depending on the starting plant and unsaturated fatty acid, for example, GLA and DGLA or SDA and ETA are formed. Preference is given to DGLA or ETA or mixtures thereof. If, in addition, ⁇ 5-desaturase is introduced into the organisms, advantageously into the plant, ARA or EPA are also produced. This also applies to organisms in which the ⁇ -8-desaturase and ⁇ -9 elongase were previously introduced.
  • the nucleic acids used in the method according to the invention are advantageously derived from plants such as algae such as Isochrysis or Crypthecodinium, algae / diatoms such as Phaeodactylum, mosses such as Physcomitrella or Ceratodon or higher plants such as the primulaceae such as Aleuritia, Calendula stellata, Osteospermum spinescens or Osteospermum hyoseroides, microorganisms such as fungi such as Aspergillus, Thraustochytrium, Phytophtora, Entomophthora, Mucor or Mortierella, yeasts or animals such as nematodes such as Caenorhabditis , insects or humans.
  • the nucleic acids are derived from fungi, animals or from plants such as algae or mosses, preferably from nematodes such as Caenorhabditis.
  • nucleic acid sequences or their derivatives or homologs which code for polypeptides which still possess the enzymatic activity of the proteins coded by the wild-type nucleic acid sequences are used.
  • These sequences are individually or in combination with the nucleic acid sequence coding for the acyl-CoA: lysophospholipid acyltransferase cloned into expression constructs and used for introduction and for expression in organisms.
  • These expression constructs enable optimal synthesis of the polyunsaturated fatty acids produced in the process according to the invention.
  • the method further comprises the step of obtaining a cell or a whole organism containing the nucleic acid sequences used in the method, wherein the cell and / or the organism with the nucleic acid sequence according to the invention, which for the acyl-CoA: lysophospholipid acyltransferase coded, a gene construct or a vector as described below, alone or in combination with other nucleic acid sequences which code for proteins of the fatty acid or lipid metabolism is transformed.
  • this method further comprises the step of recovering the fine chemical from the culture.
  • the culture may be, for example, a fermentation culture, for example in the case of culturing microorganisms such as Mortierella, Saccharomyces or Traustochytrium, or a greenhouse or field crop of a plant.
  • the cell or organism thus produced is advantageously a cell of an oil-producing organism such as an oil crop such as peanut, rape, canola, flax, hemp, peanut, soy, safflower, hemp, sunflower or borage.
  • cultivation is to be understood as cultivation on or in a nutrient medium or, in the case of the whole plant, cultivation on or in a substrate, for example in hydroponics, potting soil or on arable land.
  • Natural genetic environment means the natural genomic or chromosomal locus in the organ of origin or presence in a genomic library.
  • the natural genetic environment of the nucleic acid sequence is preferably at least partially receive.
  • the environment flanks the nucleic acid sequence at least on one side and has a sequence length of at least 50 bp, preferably at least 500 bp, more preferably at least 1000 bp, most preferably at least 5000 bp.
  • non-natural, synthetic artificial methods
  • transgenic organism or transgenic plant is to be understood as meaning that the nucleic acids used in the method are not in their natural position in the genome of an organism, wherein the nucleic acids can be expressed homologously or heterologously.
  • transgene also means that the nucleic acids according to the invention are in their natural place in the genome of an organism, but that the sequence has been changed compared to the natural sequence and / or that the regulatory sequences of the natural sequences have been altered.
  • Transgenic is preferably understood to mean the expression of the nucleic acids according to the invention at a non-natural site in the genome, that is to say a homologous or preferably heterologous expression of the nucleic acids is present.
  • Preferred transgenic organisms are fungi such as Mortierella or plants such as oil crops.
  • all organisms which are able to synthesize fatty acids, especially unsaturated fatty acids, or which are suitable for the expression of recombinant genes are suitable in principle as organisms or host organisms for the nucleic acids, expression cassettes or vectors used in the method according to the invention.
  • Examples include plants such as Arabidopsis, Asteraceae such as calendula or crops such as soy, peanut, castor, sunflower, corn, Cotton, flax, oilseed rape, coconut, oil palm, safflower ( Carthamus tinctorius ) or cocoa bean, microorganisms such as fungi of the genus Mortierella, Saprolegnia or Pythium, bacteria such as the genus Escherichia, yeasts such as the genus Saccharomyces, cyanobacteria, ciliates, algae or protozoans such as Dinoflagellates called Crypthecodinium .
  • plants such as Arabidopsis, Asteraceae such as calendula or crops such as soy, peanut, castor, sunflower, corn, Cotton, flax, oilseed rape, coconut, oil palm, safflower ( Carthamus tinctorius ) or cocoa bean
  • microorganisms such as fungi of the gen
  • organisms that can naturally synthesize oils in larger quantities such as fungi such as Mortierella alpina, Pythium insidiosum or plants such as soy, rapeseed, coconut, oil palm, Klarbersafflor, flax, hemp, castor, calendula, peanut, cocoa or sunflower or yeasts such as Saccharomyces cerevisiae, particularly preferred are soy, flax, oilseed rape, safflower, sunflower, calendula, Mortierella or Saccharomyces cerevisiae.
  • transgenic animals advantageously non-human animals such as C. elegans are suitable as host organisms in addition to the aforementioned transgenic organisms.
  • Transgenic plants which contain the polyunsaturated fatty acids synthesized in the process according to the invention can advantageously be marketed directly, without the synthesized oils, lipids or fatty acids having to be isolated.
  • Plants in the method according to the invention include whole plants and all plant tissues, plant organs or plant parts such as leaves, stems, seeds, roots, tubers, anthers, fibers, root hairs, stems, embryos, calli, kotelydons, petioles, crop material, plant tissue, reproductive tissue, Cell cultures derived from the transgenic plant and / or used to produce the transgenic plant.
  • the seed includes all seed parts such as the seed sheaths, epidermis and sperm cells, endosperm or embryonic tissue.
  • the compounds prepared in the process according to the invention can also be isolated from the organisms, advantageously plants, in the form of their oils, fats, lipids and / or free fatty acids.
  • Polyunsaturated fatty acids produced by this process can be obtained by harvesting the organisms either from the culture in which they grow or from the field. This can be done by pressing or extraction of the plant parts, preferably the plant seeds.
  • the oils, fats, lipids and / or free fatty acids can be obtained by so-called cold striking or cold pressing without supplying heat by pressing.
  • the plant parts, especially the seeds, to be easier to digest they are first crushed, steamed or roasted. The pretreated seeds can then be pressed or extracted with solvents such as warm hexane.
  • the solvent is removed again.
  • these are, for example, extracted directly after the harvest, without further operations, or after digestion, extracted by various methods known to the person skilled in the art. In this way, more than 96% of the compounds prepared in the process can be isolated.
  • the products thus obtained are further processed, that is refined.
  • the mucilages and turbid matter are removed.
  • the so-called degumming can be carried out enzymatically or, for example, chemically / physically by adding acid, such as phosphoric acid.
  • the free fatty acids are removed by treatment with a base, for example sodium hydroxide solution.
  • the product obtained is thoroughly washed with water to remove the lye remaining in the product and dried.
  • the products are subjected to bleaching with, for example, bleaching earth or activated carbon.
  • the product is deodorized, for example, with steam.
  • the PUFAs or LCPUFAs produced by this process are C 18 , C 20 or C 22 fatty acid molecules having at least two double bonds in the Fatty acid molecule, preferably three, four, five or six double bonds.
  • These C 18 , C 20 or C 22 fatty acid molecules can be isolated from the organism in the form of an oil, lipid or a free fatty acid. Suitable organisms are, for example, those mentioned above. Preferred organisms are transgenic plants.
  • One embodiment of the invention is therefore oils, lipids or fatty acids or fractions thereof prepared by the method described above, more preferably oils, lipids or a fatty acid composition comprising PUFAs derived from transgenic plants.
  • Another embodiment of the invention is the use of the oil, lipid, fatty acids and / or fatty acid composition in feed, food, cosmetics or pharmaceuticals.
  • oil is understood as meaning a fatty acid mixture which contains unsaturated, saturated, preferably esterified fatty acid (s). It is preferred that the oil, lipid or fat contain a high proportion of polyunsaturated free or advantageously esterified fatty acid (s), in particular linoleic acid, ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, arachidonic acid, ⁇ -linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, Docosapentaenoic acid or docosahexaenoic acid.
  • s polyunsaturated free or advantageously esterified fatty acid
  • the proportion of unsaturated esterified fatty acids is about 30%, more preferred is a proportion of 50%, most preferred is a proportion of 60%, 70%, 80% or more.
  • the proportion of a fatty acid can be determined by gas chromatography, for example, after conversion of the fatty acids into the methyl esters by transesterification.
  • the oil, lipid or fat may contain various other saturated or unsaturated fatty acids, eg calendulic acid, palmitic, palmitoleic, stearic, oleic acid, etc. In particular, depending on the starting organism, the proportion of the various fatty acids in the oil or fat may vary.
  • the polyunsaturated fatty acids having advantageously at least two double bonds produced in the process are, for example, sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids, monoacylglycerol, diacylglycerol, triacylglycerol or other fatty acid esters.
  • the polyunsaturated fatty acids having advantageously at least two double bonds prepared in the process according to the invention can be advantageously obtained, for example, via an alkali treatment, for example with aqueous KOH or NaOH, or acid hydrolysis in the presence of an alcohol, such as methanol or ethanol, or via enzymatic cleavage Release and isolate, for example, phase separation and subsequent acidification with eg H 2 SO 4 .
  • the release of the fatty acids can also be carried out directly without the workup described above.
  • the nucleic acids used in the method can either lie on a separate plasmid or be integrated into the genome of the host cell.
  • integration may be at random or by such recombination as to replace the native gene with the incorporated copy, thereby modulating the production of the desired compound by the cell, or by using a gene in trans such that Gene having a functional expression unit, which contains at least one expression of a gene ensuring sequence and at least one polyadenylation of a functionally transcribed gene ensuring sequence is operably linked.
  • the nucleic acids are advantageously brought into the organisms via multi-expression cassettes or constructs for multiparallel expression, advantageously for multiparallel, seed-specific expression of genes in the plants.
  • Moose and algae are the only known plant systems that contain significant amounts of polyunsaturated fatty acids such as arachidonic acid (ARA) and / or Eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).
  • ARA arachidonic acid
  • EPA Eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Moose contain PUFAs in membrane lipids, while algae, algae-related organisms and some fungi also accumulate appreciable levels of PUFAs in the triacylglycerol fraction.
  • nucleic acid molecules isolated from strains which also accumulate PUFAs in the triacylglycerol fraction are particularly advantageous for the process of the invention and thus for modification of the lipid and PUFA production system in a host, in particular plants such as oilseed crops, for example oilseed rape. Canola, flax, hemp, soy, sunflower, borage. They are therefore advantageous for use in the process according to the invention.
  • Suitable substrates of the acyl-CoA: lysophospholipid acyltransferases according to the invention are advantageously C 16 , C 18 , C 20 or C 22 fatty acids.
  • the polyunsaturated C 16 - or C 18 -fatty acids must first be desaturated by the enzymatic activity of a desaturase and then be extended by at least two carbon atoms via an elongase. After one round of elongation this enzyme activity leads to C 18 or C 20 fatty acids, and after two or three rounds of elongation to C 22 or C 24 fatty acids.
  • the activity of the desaturases and elongases used in the process according to the invention preferably leads to C 18 , C 20 and / or C 22 fatty acids, advantageously having at least two double bonds in the fatty acid molecule, preferably having three, four or five double bonds, more preferably C 20 - and / or C 22 fatty acids having at least two double bonds in the fatty acid molecule, preferably having three, four or five double bonds in the molecule.
  • further desaturation steps such as those in the ⁇ -5 position, can take place.
  • Particularly preferred as products of the process according to the invention are dihomo- ⁇ -linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and / or docosahexaenoic acid.
  • the C 18 fatty acids with at least two double bonds in the fatty acid can be prolonged by the enzymatic activity according to the invention in the form of the free fatty acid or in the form of the esters, such as phospholipids, glycolipids, sphingolipids, phosphoglycerides, monoacylglycerol, diacylglycerol or triacylglycerol.
  • the preferred biosynthesis site of fatty acids, oils, lipids or fats in the advantageously used plants is, for example, the seed in general or cell layers of the seed, so that a seed-specific expression of the nucleic acids used in the method makes sense.
  • the biosynthesis of fatty acids, oils or lipids need not be limited to the seed tissue but can also be tissue-specific in all other parts of the plant - for example in epidermal cells or in the tubers.
  • the amount of polyunsaturated fatty acids produced in the process can be at least 10%, preferably at least 15%, particularly preferably at least 20%, very particularly preferably at least 50%, and most preferably at least 100%, of the wild type of organisms which do not recombinantly contain the nucleic acids.
  • the polyunsaturated fatty acids produced in the organisms used in the process can in principle be increased in two ways.
  • the pool of free polyunsaturated fatty acids and / or the proportion of esterified polyunsaturated fatty acids produced by the process can be increased.
  • the process according to the invention increases the pool of esterified polyunsaturated fatty acids in the transgenic organisms.
  • microorganisms such as yeasts such as Saccharomyces or Schizosaccharomyces, fungi such as Mortierella, Aspergillus, Phytophtora, Entomophthora, Mucor or Traustochytrium, algae such as Isochrysis, Phaeodactylum or Crypthecodinium are used in the method according to the invention , these organisms are advantageously cultivated by fermentation in a manner known to those skilled in the art or bred.
  • Microorganisms are usually in a liquid medium containing a carbon source usually in the form of sugars, a nitrogen source usually in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese, magnesium salts and optionally vitamins, at temperatures between 0 ° C and 100 ° C, preferably between 10 ° C to 60 ° C attracted under oxygen fumigation.
  • a carbon source usually in the form of sugars
  • a nitrogen source usually in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate
  • trace elements such as iron, manganese, magnesium salts and optionally vitamins
  • the pH of the nutrient fluid can be kept at a fixed value, that is, regulated during cultivation, or not.
  • the cultivation can be batchwise, semi-batchwise or continuous. Nutrients can be presented at the beginning of the fermentation or fed in semi-continuously or continuously.
  • the polyunsaturated fatty acids prepared can be isolated from the organisms by methods known to those skilled in the art, for example by extraction, distillation, crystallization, optionally salt precipitation and / or chromatography as described above.
  • the organisms can be opened up for this purpose yet advantageous.
  • the method according to the invention when the host organisms are microorganisms, is advantageously at a temperature between 0 ° C to 95 ° C, preferably between 10 ° C to 85 ° C, more preferably between 15 ° C to 75 ° C, and most preferably carried out between 15 ° C to 45 ° C
  • the pH is advantageously maintained between pH 4 and 12, preferably between pH 6 and 9, more preferably between pH 7 and 8.
  • the process according to the invention can be operated batchwise, semi-batchwise or continuously.
  • a summary of known cultivation methods is in the textbook by Chmiel (Bioreatechnik 1. Introduction to Bioprocess Engineering (Gustav Fischer Verlag, Stuttgart, 1991 )) or in the textbook von Storhas (bioreactors and peripheral facilities (Vieweg Verlag, Braunschweig / Wiesbaden, 1994 )) to find.
  • the culture medium to be used must suitably satisfy the requirements of the respective strains. Descriptions of culture media of various microorganisms are in the handbook " Manual of Methods for General Bacteriology of the American Society of Bacteriology (Washington DC, USA, 1981 ) contain.
  • these media which can be used according to the invention usually comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.
  • Preferred carbon sources are sugars, such as mono-, di- or polysaccharides.
  • sugars such as mono-, di- or polysaccharides.
  • very good sources of carbon are glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose.
  • Sugar may also be added to the media via complex compounds, such as molasses or other by-products of sugar refining. It may also be advantageous to add mixtures of different carbon sources.
  • Other possible sources of carbon are oils and fats such. As soybean oil, sunflower oil, peanut oil and / or coconut oil, fatty acids such.
  • Nitrogen sources are usually organic or inorganic nitrogen compounds or materials containing these compounds.
  • Exemplary nitrogen sources include ammonia in liquid or gaseous form or Ammonium salts such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources such as corn steep liquor, soybean meal, soy protein, yeast extract, meat extract and others.
  • the nitrogen sources can be used singly or as a mixture.
  • Inorganic salt compounds which may be included in the media include the chloride, phosphate or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
  • sulfur-containing fine chemicals in particular methionine
  • inorganic sulfur-containing compounds such as sulfates, sulfites, dithionites, tetrathionates, thiosulfates, sulfides but also organic sulfur compounds, such as mercaptans and thiols can be used.
  • Phosphoric acid potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium salts can be used as the phosphorus source.
  • Chelating agents can be added to the medium to keep the metal ions in solution.
  • Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
  • the fermentation media used according to the invention for the cultivation of microorganisms usually also contain other growth factors such as vitamins or growth promoters, which include, for example, biotin, riboflavin, thiamine, folic acid, nicotinic acid, panthothenate and pyridoxine.
  • Growth factors and salts are often derived from complex media components such as yeast extract, molasses, corn steep liquor, and the like.
  • suitable precursors can be added to the culture medium.
  • the exact composition of the media compounds depends strongly on the respective experiment and is decided individually for each specific case. Information about media optimization is available from the Textbook "Applied Microbiol. Physiology, A Practical Approach” (Editor PM Rhodes, PF Stanbury, IRL Press (1997) pp. 53-73, ISBN 019963577 3 ).
  • Growth media may also be obtained from commercial suppliers such as Standard 1 (Merck) or BHI (Brain heart infusion, DIFCO) and the like.
  • All media components are sterilized either by heat (20 min at 1.5 bar and 121 ° C) or by sterile filtration.
  • the components can either be sterilized together or, if necessary, sterilized separately. All media components may be present at the beginning of the culture or optionally added continuously or batchwise.
  • the temperature of the culture is usually between 15 ° C and 45 ° C, preferably 25 ° C to 40 ° C and can be kept constant or changed during the experiment.
  • the pH of the medium should be in the range of 5 to 8.5, preferably around 7.0.
  • the pH for cultivation can be controlled during cultivation by addition of basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acidic compounds such as phosphoric acid or sulfuric acid.
  • B. fatty acid polyglycol esters are used.
  • the medium can be selected selectively acting substances such. As antibiotics, are added.
  • oxygen or oxygen-containing gas mixtures such. B. ambient air, registered in the culture. The culture is continued until a maximum of the desired product has formed. This goal is usually reached within 10 hours to 160 hours.
  • the fermentation broths thus obtained in particular containing polyunsaturated fatty acids, usually have a dry matter content of 7.5 to 25% by weight.
  • the fermentation broth can then be further processed.
  • the biomass can be wholly or partly by separation methods, such. As centrifugation, filtration, decantation or a combination of these methods are removed from the fermentation broth or completely left in it.
  • the biomass is worked up after separation.
  • the fermentation broth can also without cell separation with known methods such.
  • production or productivity are known in the art and include the concentration of the fermentation product (compounds of formula I) formed in a given period of time and fermentation volume (eg, kg of product per hour per liter).
  • efficiency of production includes the time required to reach a certain amount of production (eg, how long the cell needs to set up a specific throughput rate of a fine chemical).
  • yield or product / carbon yield is known in the art and includes the efficiency of converting the carbon source into the product (ie, the fine chemical). This is usually expressed, for example, as kg of product per kg of carbon source.
  • biosynthesis or biosynthetic pathway are known in the art and include the synthesis of a compound, preferably an organic compound, through a cell of intermediates, for example in a multi-step and highly regulated process.
  • degradation or degradation pathway are well known in the art and involve the cleavage of a compound, preferably an organic compound, by a cell into degradation products (more generally, smaller or less complex molecules), for example in a multi-step and highly regulated process.
  • metabolism is known in the art and includes the entirety of the biochemical reactions that take place in an organism. The metabolism of a particular compound (eg, the metabolism of a fatty acid) then comprises the entirety of the biosynthesis, modification, and degradation pathways of that compound in the cell that affect that compound.
  • the fatty acids obtained in the process are also suitable as starting material for the chemical synthesis of further products of value.
  • they may be used in combination with each other or alone for the production of pharmaceuticals, foods, pet foods or cosmetics.
  • nucleic acid sequences originate from a eukaryotic organism, more preferably from Ostreococcus tauri or Mantoniella squamata.
  • the nucleic acids used in the method are advantageously subjected to amplification and ligation in a known manner.
  • the procedure is based on the protocol of the Pfu DNA polymerase or of a Pfu / Taq DNA polymerase mixture.
  • the primers are selected on the basis of the sequence to be amplified. Conveniently, the primers should be chosen so that the amplificate comprises the entire codogenic sequence from the start to the stop codon.
  • the amplificate is conveniently analyzed. For example, the analysis can be carried out after gel electrophoretic separation in terms of quality and quantity. Subsequently, the amplificate can be purified according to a standard protocol (eg Qiagen).
  • Suitable cloning vectors are well known to those skilled in the art. These include, in particular, vectors which can be replicated in microbial systems, that is, above all, vectors which ensure efficient cloning in yeasts or fungi and at the same time enable the stable transformation of plants. Particularly noteworthy are various for the T-DNA mediated Transformation suitable, binary and co-integrated vector systems. Such vector systems are usually characterized in that they contain at least the vir genes required for the Agrobacterium-mediated transformation as well as the T-DNA-limiting sequences (T-DNA border).
  • these vector systems also include other cis-regulatory regions, such as promoters and terminators and / or selection markers, with which appropriately transformed organisms can be identified.
  • vir genes and T-DNA sequences are located on the same vector
  • binary systems are based on at least two vectors, one of them vir genes, but no T-DNA and a second T-DNA, but no carries vir gene.
  • the latter vectors are relatively small, easy to manipulate and replicate in both E. coli and Agrobacterium .
  • These binary vectors include vectors of the series pBIB-HYG, pPZP, pBecks, pGreen.
  • the vectors can first be linearized with restriction endonuclease (s) and then enzymatically modified in a suitable manner. The vector is then purified and an aliquot used for cloning. In cloning, the enzymatically cut and, if necessary, purified amplicon is cloned with similarly prepared vector fragments using ligase.
  • restriction endonuclease s
  • a particular nucleic acid construct or vector or plasmid construct can have one or more codogenic gene segments.
  • the codogenic gene segments in these constructs are functionally linked to regulatory sequences.
  • the regulatory sequences include, in particular, plant sequences such as the promoters and terminators described above.
  • the constructs can advantageously be stably propagated in microorganisms, in particular Escherichia coli and Agrobacterium tumefaciens, under selective conditions and enable a transfer of heterologous DNA into plants or microorganisms.
  • nucleic acids used in the method can be introduced into organisms such as microorganisms or advantageously plants and thus used in plant transformation, such as those published in and cited therein: Plant Molecular Biology and Biotechnology (CRC Press, Boca Raton, Florida), Chapter 6/7, pp. 71-119 (1993 ); FF White, Vectors for Gene Transfer to Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds .: Kung and R. Wu, Academic Press, 1993, 15-38 ; Techniques for Gene Transfer, Transgenic Plants, Vol. 1, Engineering and Utilization, eds. Kung and R.
  • nucleic acids used in the method, the inventive nucleic acids and nucleic acid constructs and / or vectors can thus be used for the genetic modification of a broad spectrum of organisms, advantageously on plants, so that they become better and / or more efficient producers of PUFAs.
  • acyl-CoA lysophospholipid acyltransferase protein of the present invention
  • the number or activity of the acyl-CoA: lysophospholipid acyltransferase protein or gene and of the gene combinations of acyl-CoA: lysophospholipid acyltransferases, desaturases and / or elongases may be increased so that larger amounts of the compounds produced are produced de novo, because the organisms lacked this activity and ability to biosynthesize before introducing the corresponding gene (s).
  • acyl-CoA lysophospholipid-acyltransferase, desaturase and / or elongase gene or several acyl-CoA: lysophospholipid-acyltransferase, desaturase and / or elongase genes alone or in combination with other genes into an organism
  • acyl-CoA lysophospholipid-acyltransferase, desaturase and / or elongase genes alone or in combination with other genes
  • the number or activity of other genes required to import nutrients needed for the biosynthesis of one or more fine chemicals may be increased, such that the concentration of these precursors, cofactors or intermediates within the cells or within the storage compartment, thereby further increasing the ability of the cells to produce PUFAs, as described below.
  • Fatty acids and lipids are desirable even as fine chemicals; by optimizing the activity or increasing the number of one or more acyl-CoA: lysophospholipid acyltransferases, desaturases and / or elongases involved in the biosynthesis of these compounds or by disrupting the activity of one or more desaturases involved in the degradation of these compounds It may be possible to increase the yield, production and / or efficiency of the production of fatty acid and lipid molecules from organisms and, advantageously, from plants.
  • the isolated nucleic acid molecules used in the method according to the invention encode proteins or parts thereof, wherein the proteins or the individual protein or parts thereof contain an amino acid sequence which is sufficiently homologous to an amino acid sequence of the sequence SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6 is such that the protein or portion thereof has an acyl-CoA: lysophospholipid acyltransferase activity maintains.
  • the protein or portion thereof encoded by the nucleic acid molecule still has its essential enzymatic activity and has the ability to interfere in the metabolism of compounds necessary for building cell membranes or lipid bodies in organisms, advantageously in plants, or in the transport of To participate in molecules via these membranes.
  • the protein encoded by the nucleic acid molecules is at least about 40%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and most preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an amino acid sequence of the sequence SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6.
  • SEQ ID NO: 2 amino acid sequence of the sequence SEQ ID NO: 4 or SEQ ID NO: 6.
  • lysophospholipid acyltransferases used is to be understood as meaning that they differ from the proteins / enzymes encoded by the sequence with SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 and their derivatives in the Comparative still have an enzymatic activity of at least 10%, preferably at least 20%, more preferably at least 30% and most preferably at least 40% and thus the metabolism of the structure of fatty acids in an organism, preferably a plant cell, necessary compounds or transport of molecules via membranes, denatured C16, C18, C20 or C24 carbon chains having double bonds at at least two, preferably three, four or five positions.
  • Nucleic acids useful in the method are derived from fungi or plants such as algae or mosses such as the genera Physcomitrella, Thraustochytrium, Phytophthora, Ceratodon, Isochrysis, Aleurita, Muscarioides, Mortierella, Borago, Phaeodactylum, Crypthecodinium or from nematodes such as Caenorhabditis, especially from the genera and species Physcomitrella patens, Phytophthora infestans, Ceratodon purpureus, Isochrysis galbana, Aleurita farinosa, Muscarioides viallii, Mortierella alpina, Borago officinalis, Phaeodactylum tricornutum or particularly advantageous from Ostreococcus tauri or Mantoniella squamata.
  • fungi or plants such as algae or mosses such as the genera Physcomit
  • the isolated nucleotide sequences used may encode acyl-CoA: lysophospholipid acyltransferases which hybridize to a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, e.g. under stringent conditions.
  • the nucleic acid sequences used in the method are advantageously introduced into the respective organism in an expression cassette which enables expression of the nucleic acids in organisms such as microorganisms or plants.
  • nucleic acid sequences coding for the inventive acyl-CoA: lysophospholipid acyltransferases, the desaturases used and / or the elongases are advantageously linked functionally to one or more regulatory signals in order to increase gene expression.
  • These regulatory sequences are intended to allow the targeted expression of genes and proteins. Depending on the host organism, this may mean, for example, that the gene is expressed and / or overexpressed only after induction, or that it is expressed and / or overexpressed immediately.
  • these regulatory sequences are sequences to which inducers or repressors bind and thus regulate the expression of the nucleic acid.
  • the natural regulation of these sequences may still be present before the actual structural genes and may have been genetically altered so that natural regulation is eliminated and gene expression increased.
  • the gene construct may advantageously also contain one or more so-called “enhancer sequences” functionally linked to the promoter, which allow increased expression of the nucleic acid sequence. Additional advantageous sequences can also be inserted at the 3 'end of the DNA sequences, such as further regulatory elements or terminators.
  • gene construct gene construct
  • This gene construct or gene constructs can be expressed together in the host organism.
  • the gene construct or the gene constructs can be inserted in one or more vectors and be present freely in the cell or else be inserted in the genome. It is advantageous for the insertion of further genes into the host genome when the genes to be expressed are present together in a gene construct.
  • the regulatory sequences or factors may, as described above, preferably positively influence the expression of the introduced genes and thereby increase them.
  • enhancement of the regulatory elements can advantageously be done at the transcriptional level by using strong transcription signals such as promoters and / or enhancers.
  • an enhancement of the translation is possible by, for example, the stability of the mRNA is improved.
  • a further embodiment of the invention are one or more gene constructs which contain one or more sequences which are defined by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 or their derivatives and for polypeptides according to SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6.
  • the said acyl-CoA: lysophospholipid acyltransferases lead to an exchange of the fatty acids between the mono-, di- and / or triglyceride pool of the cell and the CoA fatty acid ester pool, the substrate advantageously one, two, three, four or five Double bonds and advantageously has 16, 18, 20, 22 or 24 carbon atoms in the fatty acid molecule.
  • Advantageous regulatory sequences for the novel process are, for example, in promoters such as the cos, tac, trp, tet, trp tet, lpp, lac, lpp-lac, lacIq, T7, T5, T3 , gal, trc, ara, SP6, ⁇ -PR or ⁇ -PL promoter and are advantageously used in Gram-negative bacteria.
  • Further advantageous regulatory sequences are, for example, in the Gram-positive promoters amy and SPO2, in the yeast or fungal promoters ADC1, MF ⁇ , AC, P-60, CYC1, GAPDH, TEF, rp28, ADH or in the plant promoters CaMV / 35S ( Franck et al.
  • inducible promoters such as those in EP-A-0 388 186 (Benzylsulfonamide-inducible), Gatz et al. (1992) Plant J. 2: 397-404 (Tetracycline inducible), EP-A-0 335 528 (Abszisin Textre inducible) or WO 93/21334 (Ethanol or cyclohexenol inducible) promoters described.
  • cytosolic FBPase promoter or the potato ST-LSI promoter ( Stockhaus et al. (1989) EMBO J. 8: 2445 ), the glycine max phosphoribosyl-pyrophosphate amidotransferase promoter (Genbank Accession No. U87999) or the EP-A-0 249 676 described nodia-specific promoter.
  • Particularly advantageous promoters are promoters that allow expression in tissues involved in fatty acid biosynthesis.
  • seed-specific promoters such as the USP promoter according to the embodiment, but also other promoters such as the LeB4, DC3, phaseolin or napin promoter.
  • promoters are seed-specific promoters which can be used for monocotyledonous or dicotyledonous plants and in US 5,608,152 (Napin promoter from rapeseed), WO 98/45461 (Oleosin promoter from Arobidopsis), US 5,504,200 (Phaseolin promoter from Phaseolus vulgaris), WO 91/13980 (Bce4 promoter from Brassica), Baeumlein et al. (1992) Plant J. 2 (2): 233-239 (LeB4 promoter from a legume) are described, these promoters are suitable for dicotyledons.
  • promoters are suitable, for example, for monocotyledons: lpt-2 or lpt-1 promoter from barley ( WO 95/15389 and WO 95/23230 ), Hordein promoter from barley and others, in WO 99/16890 described suitable promoters.
  • the PUFA biosynthesis genes should advantageously be seed-specifically expressed in oilseeds.
  • seed-specific promoters can be used or promoters that are active in the embryo and / or in the endosperm.
  • seed-specific promoters can be isolated from both dicotyledonous and monocotyledonous plants.
  • Plant gene expression can also be achieved via a chemically inducible promoter (see Overview in Gatz (1997) Annu. Rev. Plant Physiol. Plant Mol. Biol. 48: 89-108 ).
  • Chemically inducible promoters are particularly useful when it is desired that gene expression be in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter ( WO 95/19443 ), a tetracycline-inducible promoter ( Gatz et al. (1992) Plant J. 2: 397-404 ) and an ethanol-inducible promoter.
  • each of the nucleic acids used in the process, for the acyl-CoA lysophospholipid acyltransferase, the beneficial ⁇ -4-desaturase, the ⁇ -5-desaturase, the ⁇ 6-desaturase encoding ⁇ 8-desaturase and / or ⁇ 5-elongase, ⁇ 6-elongase and / or ⁇ 9-elongase, under the control of a distinct, preferably a different, promoter because repetitive sequence motifs can lead to instability of the T-DNA or to recombination events.
  • the expression cassette is advantageously constructed so that a promoter is followed by a suitable interface for insertion of the nucleic acid to be expressed, which is advantageously in a polylinker and optionally followed by a terminator.
  • This sequence is repeated several times, preferably three, four or five times, so that up to five genes combined in one construct and so for expression in the transgenic plant can be introduced.
  • the sequence is repeated up to three times.
  • the nucleic acid sequences are inserted for expression via the appropriate interface, for example in the polylinker behind the promoter.
  • each nucleic acid sequence has its own promoter and optionally its own terminator. However, it is also possible to insert several nucleic acid sequences behind a promoter and possibly in front of a terminator.
  • the insertion site or the sequence of the inserted nucleic acids in the expression cassette is not of decisive importance, that is, a nucleic acid sequence may be inserted at the first or last position in the cassette, without this significantly affecting the expression.
  • different promoters such as the USP, LegB4 or DC3 promoter and different terminators may be used in the expression cassette. But it is also possible to use only one type of promoter in the cassette. However, this can lead to unwanted recombination events.
  • the transcription of the introduced genes should advantageously be stopped by suitable terminators at the 3 'end of the introduced biosynthesis genes (behind the stop codon). It can be used here e.g. the OCS1 terminator. As for the promoters, different terminator sequences should be used for each gene.
  • the gene construct may, as described above, also include other genes to be introduced into the organisms. It is possible and advantageous to introduce into the host organisms regulatory genes, such as genes for inducers, repressors or enzymes, which intervene by their enzyme activity in the regulation of one or more genes of a biosynthetic pathway, and to express therein. These genes may be of heterologous or homologous origin. Furthermore, further biosynthesis genes of the fatty acid or lipid metabolism can be advantageously contained in the nucleic acid construct or gene construct, or else these genes can be present lie on one or more further nucleic acid constructs.
  • the biosynthesis gene of the fatty acid or lipid metabolism is a gene selected from the group consisting of acyl-CoA dehydrogenase (s), acyl-ACP [acyl carrier protein] desaturase (s), acyl-ACP thioesterase (s), Fatty acid acyltransferase (s), fatty acid synthase (s), fatty acid hydroxylase (s), acetyl coenzyme A carboxylase (s), acyl coenzyme A oxidase (s), fatty acid desaturase (s), Fatty acid acetylenases, lipoxygenases, triacylglycerol lipases, allene oxide synthases, hydroperoxide lyases or fatty acid elongase (s), or a combination of these genes.
  • acyl-CoA dehydrogenase s
  • acyl-ACP [acyl carrier protein] desaturase
  • nucleic acid sequences are biosynthesis genes of the fatty acid or lipid metabolism selected from the group of ⁇ -4-desaturase, ⁇ -5-desaturase, ⁇ -6-desaturase, ⁇ -8-desatuase, ⁇ -9-desaturase, ⁇ 12-desaturase, ⁇ 5-elongase, ⁇ 6-elongase or ⁇ -9 elongase genes.
  • the abovementioned desaturases can be cloned in combination with other elongases and desaturases into expression cassettes according to the invention and used for the transformation of plants with the aid of Agrobacterium.
  • the regulatory sequences or factors can, as described above, preferably positively influence the gene expression of the introduced genes and thereby increase them.
  • enhancement of the regulatory elements can advantageously be done at the transcriptional level by using strong transcription signals such as promoters and / or enhancers.
  • an enhancement of the translation is possible by, for example, the stability of the mRNA is improved.
  • the expression cassettes can be used in principle directly for introduction into the plant or else be introduced into a vector.
  • These advantageous vectors contain the nucleic acids encoding acyl-CoA: lysophospholipid acyltransferases used in the method, or a nucleic acid construct using them Nucleic acid alone or in combination with other biosynthesis genes of fatty acid or lipid metabolism such as ⁇ -4-desaturase, ⁇ -5-desaturase, ⁇ -6-desaturase, ⁇ -8-desatuase, ⁇ -9-desaturase, ⁇ -12-desaturase, ⁇ -5-elongase, ⁇ -6-elongase and / or ⁇ -9-elongase genes.
  • vector refers to a nucleic acid molecule that can transport another nucleic acid to which it is attached.
  • plasmid which is a circular double-stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector Another type of vector is a viral vector, where additional DNA segments can be ligated into the viral genome.
  • Certain vectors may autonomously replicate in a host cell into which they have been introduced (eg bacterial vectors of bacterial origin of replication). Other vectors are advantageously integrated into the genome of a host cell upon introduction into the host cell and thereby replicated together with the host genome.
  • certain vectors may direct the expression of genes to which they are operably linked.
  • expression vectors suitable for recombinant DNA techniques are in the form of plasmids.
  • plasmid and “vector” can be used interchangeably because the plasmid is the most commonly used vector form.
  • the invention is intended to encompass other forms of expression vectors, such as viral vectors that perform similar functions.
  • vector is also intended to encompass other vectors known to those skilled in the art, such as phages, viruses such as SV40, CMV, TMV, transposons, IS elements, phasmids, phagemids, cosmids, linear or circular DNA.
  • the recombinant expression vectors advantageously used in the method comprise the below-described nucleic acids or the above-described gene construct in a form suitable for expression of the nucleic acids used in a host cell, which means that the recombinant expression vectors have one or more regulatory sequences selected on the Base of the host cells to be used for expression which is operably linked to the nucleic acid sequence to be expressed.
  • operatively linked means that the nucleotide sequence of interest is bound to the regulatory sequence (s) such that expression of the nucleotide sequence is possible and they are linked together such that both sequences fulfill the predicted function ascribed to the sequence (eg in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell).
  • regulatory sequence is intended to include promoters, enhancers, and other expression control elements (eg, polyadenylation signals).
  • Regulatory sequences include those that direct the constitutive expression of a nucleotide sequence in many types of host cells, and those that direct the direct expression of the nucleotide sequence only in certain host cells under certain conditions.
  • the design of the expression vector may depend on factors such as the selection of the host cell to be transformed, the level of expression of the desired protein, etc.
  • acyl-CoA lysophospholipid acyltransferases, desaturases and elongases in prokaryotic or eukaryotic cells. This is advantageous since intermediate steps of the vector construction are often carried out in microorganisms for the sake of simplicity.
  • acyl-CoA lysophospholipid acyltransferase, desaturase and / or elongase genes can be detected in bacterial cells, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, MA, et al.
  • Typical fusion expression vectors include pGEX ( Pharmacia Biotech Inc .; Smith, DB, and Johnson, KS (1988) Gene 67: 31-40 pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ), in which glutathione-S-transferase (GST), Maltose E-binding protein or protein A is fused to the recombinant target protein.
  • GST glutathione-S-transferase
  • Suitable inducible non-fusion E. coli expression vectors include pTrc ( Amann et al. (1988) Gene 69: 301-315 ) and pET 11d ( Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89 ).
  • Target gene expression from the pTrc vector is based on transcription by host RNA polymerase from a hybrid trp-lac fusion promoter.
  • Target gene expression from the pET 11d vector is based on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is provided in the host strains BL21 (DE3) or HMS 174 (DE3) by a resident ⁇ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.
  • vectors in prokaryotic organisms are known to those skilled in the art, these vectors are, for example, in E. coli pLG338, pACYC184, the pBR series, such as pBR322, the pUC series, such as pUC18 or pUC 19, the M113mp series, pKC30, pRep4 , pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113B1, ⁇ gt11 or pBdCI, in Streptomyces pIJ101, pIJ364, pIJ702 or pIJ361, in Bacillus pUB110, pC194 or pBD214, in Corynebacterium pSA77 or pAJ667.
  • the expression vector is a yeast expression vector.
  • yeast expression vectors for expression in the yeast S. cerevisiae include pYeDesaturasec1 ( Baldari et al. (1987) Embo J. 6: 229-234 ), pMFa ( Kurjan and Herskowitz (1982) Cell 30: 933-943 ), pJRY88 ( Schultz et al. (1987) Gene 54: 113-123 ) and pYES2 (Invitrogen Corporation, San Diego, CA).
  • Vectors and methods for constructing vectors suitable for use in other fungi, such as filamentous fungi include those described in detail in: van den Hondel, CAMJJ, & Punt, PJ (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of fungi, JF Peberdy et al., Eds., Pp. 1-28, Cambridge University Press: Cambridge , or in: More Gene Manipulations in Fungi (JW Bennet & LL Lasure, Eds., Pp. 396-428: Academic Press: San Diego ).
  • Other suitable yeast vectors are, for example, pAG-1, YEp6, YEp13 or pEMBLYe23.
  • acyl-CoA lysophospholipid acyltransferases, desaturases and / or elongases
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series ( Smith et al. (1983) Mol. Cell Biol. 3: 2156-2165 ) and the pVL series ( Lucklow and Summers (1989) Virology 170: 31-39 ).
  • the acyl-CoA lyso-phospholipid acyltransferases, desaturases and / or elongases in unicellular plant cells (such as algae), see Falciatore et al., 1999, Marine Biotechnology 1 (3): 239-251 and references cited therein, and plant cells from higher plants (eg, spermatophytes, such as crops) are expressed.
  • plant expression vectors include those described in detail in: Becker, D., Kemper, E., Schell, J., and Masterson, R. (1992) Plant Mol. Biol. 20: 1195-1197 ; and Bevan, MW (1984) Nucl. Acids Res. 12: 8711-8721 ; Vectors for Gene Transfer to Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds .: Kung and R. Wu, Academic Press, 1993, pp. 15-38 ,
  • a plant expression cassette preferably contains regulatory sequences that can direct gene expression in plant cells and are operably linked so that each sequence can perform its function, such as termination of transcription, for example, polyadenylation signals.
  • Preferred polyadenylation signals are those derived from Agrobacterium tumefaciens T-DNA, such as the gene 3 of the Ti plasmid pTiACH5 known as octopine synthase ( Gielen et al., EMBO J. 3 (1984) 835ff .) or functional equivalents thereof, but also all other terminators functionally active in plants are suitable.
  • a plant expression cassette preferably contains other operably linked sequences, such as translation enhancers, such as the overdrive sequence containing the 5'-untranslated tobacco mosaic virus leader sequence, which is the protein / RNA ratio increases, contains ( Gallie et al. (1987) Nucl. Acids Research 15: 8693-8711 ).
  • the gene to be expressed must, as described above, be operably linked to a suitable promoter that performs gene expression in a timely, cell or tissue-specific manner.
  • suitable promoters are constitutive promoters ( Benfey et al. (1989) EMBO J. 8: 2195-2202 ), such as those derived from plant viruses, such as 35S CAMV ( Franck et al. (1980) Cell 21: 285-294 ), 19S CaMV (see also US 5,352,605 and WO 84/02913 ) or plant promoters, such as those in US 4,962,028 described the small subunit of Rubisco.
  • sequences for use in the functional compound in plant gene expression cassettes are targeting sequences used to direct the gene product into its corresponding cell compartment, for example, the vacuole, nucleus, all types of plastids, such as amyloplasts, chloroplasts, chromoplasts, extracellular Space, the mitochondria, the endoplasmic reticulum, oil bodies, peroxisomes and other compartments of plant cells, are necessary (see an overview in Kermode (1996) Crit. Rev. Plant Sci. 15, 4: 285-423 and references cited therein).
  • Plant gene expression can also be facilitated via a chemically inducible promoter as described above (see Overview in Gatz (1997) Annu. Rev. Plant Physiol. Plant Mol. Biol. 48: 89-108 ).
  • Chemically inducible promoters are particularly useful when it is desired that gene expression be in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter ( WO 95/19443 ), a tetracycline-inducible promoter ( Gatz et al. (1992) Plant J. 2: 397-404 ) and an ethanol-inducible promoter.
  • Promoters which react to biotic or abiotic stress conditions are also suitable promoters, for example the pathogen-induced PRP1 gene promoter ( Ward et al. (1993) Plant. Mol. Biol. 22: 361-366 ), the heat-inducible hsp80 promoter from tomato ( US 5,187,267 ), the potash-inducible alpha-amylase promoter from potato ( WO 96/12814 ) or the wound-inducible pinII promoter ( EP-A-0 375 091 ).
  • the pathogen-induced PRP1 gene promoter Ward et al. (1993) Plant. Mol. Biol. 22: 361-366
  • the heat-inducible hsp80 promoter from tomato US 5,187,267
  • the potash-inducible alpha-amylase promoter from potato WO 96/12814
  • the wound-inducible pinII promoter EP-A-0 375 091 .
  • promoters which induce gene expression in tissues and organs in which fatty acid, lipid and oil biosynthesis takes place in sperm cells such as the cells of the endosperm and the developing embryo.
  • Suitable promoters are the Napingen promoter from rapeseed ( US 5,608,152 ), the USP promoter from Vicia faba ( Baeumlein et al. (1991) Mol Gen Genet.
  • the Arabidopsis oleosin promoter ( WO 98/45461 ), the phaseolin promoter from Phaseolus vulgaris ( US 5,504,200 ), the Bce4 promoter from Brassica ( WO 91/13980 ) or the legumin B4 promoter (LeB4; Baeumlein et al. (1992) Plant Journal 2 (2): 233-9 ) as well as promoters, which bring about the seed-specific expression in monocotyledonous plants such as corn, barley, wheat, rye, rice, etc.
  • Suitable promoters are the lpt2 or lpt1 gene promoter from barley ( WO 95/15389 and WO 95/23230 ) or the in WHERE 99/16890 (promoters from the barley hordein gene, the rice glutelin gene, the rice oryzine gene, the rice prolamin gene, the wheat gliadin gene, the wheat glutelin gene, the maize zein Gene, the oat glutelin gene, the sorghum-kasirin gene, the rye-secalin gene).
  • promoters which induce plastid-specific expression, since plastids are the compartment in which the precursors as well as some end products of lipid biosynthesis are synthesized.
  • Suitable promoters are the viral RNA polymerase promoter described in WO 95/16783 and WO 97/06250 , and the clpP promoter from Arabidopsis, which in WO 99/46394 is described.
  • the multiparallel expression of the acyl-CoA: lysophospholipid acyltransferases used in the process may be desired alone or in combination with desaturases and / or elongases.
  • the introduction of such expression cassettes can be carried out via a simultaneous transformation of a plurality of individual expression constructs or preferably by combining a plurality of expression cassettes on a construct.
  • multiple vectors, each containing multiple expression cassettes can be transformed and transferred to the host cell.
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection,” conjugation and transduction are intended to encompass a variety of methods known in the art for introducing foreign nucleic acids (eg, DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE- Dextran-mediated transfection, lipofection, natural competence, chemically mediated transfer, electroporation or particle bombardment.
  • Suitable methods for transforming or transfecting host cells, including plant cells can be found in US Pat Sambrook and Russell (Molecular Cloning: A Laboratory Manual.
  • Host cells which are suitable in principle for receiving the nucleic acid according to the invention, the gene product according to the invention or the vector according to the invention are all prokaryotic or eukaryotic organisms.
  • the host organisms which are advantageously used are microorganisms, such as fungi or yeasts or plant cells, preferably plants or parts thereof.
  • Fungi, yeasts or plants are preferably used, more preferably plants, most preferably plants such as oilseed crops containing high levels of lipid compounds such as rapeseed, evening primrose, hemp, thistle, peanut, canola, flax, soybean, safflower, sunflower, borage , or plants such as corn, wheat, rye, oats, triticale, rice, barley, cotton, cassava, pepper, tagetes, solanaceae plants such as potato, tobacco, eggplant and tomato, vicia species, pea, alfalfa, bush plants (coffee, Cocoa, tea), Salix species, trees (oil plan, coconut) and perennial grasses and forage crops.
  • Particularly preferred plants according to the invention are oil crop plants, such as soybean, peanut, rapeseed, canola, flax, hemp, evening primrose, sunflower, safflower, trees (oil palm, coconut).
  • a further subject of the invention are isolated nucleic acid sequences encoding acyl-CoA: lysophospholipid acyltransferase activity polypeptides as described above, wherein the acyl-CoA: lysophospholipid acyltransferases encoded by the nucleic acid sequences are C 16 , C 18 , C 20 or C 16 C 22 -fatty acids with at least one double bond in the fatty acid molecule implement.
  • nucleic acid sequences of the invention are derived from organisms such as animals, ciliates, fungi, plants such as algae or dinoflagellates which are capable of synthesizing PUFAs.
  • the nucleic acid sequences according to the invention are derived from Ostreococcus tauri or Mantonella squamata.
  • nucleic acid (molecule) also comprises, in an advantageous embodiment, the untranslated sequence located at the 3 'and 5' end of the coding gene region: at least 500, preferably 200, more preferably 100 nucleotides of the sequence upstream of the 5 'end of the coding region and at least 100, preferably 50, more preferably 20 nucleotides of the sequence downstream of the 3' end of the coding gene region.
  • An "isolated" nucleic acid molecule is separated from other nucleic acid molecules present in the natural source of the nucleic acid.
  • an "isolated" nucleic acid preferably does not have sequences that naturally flank the nucleic acid in the genomic DNA of the organism from which the nucleic acid is derived (eg, sequences located at the 5 'and 3' ends of the nucleic acid) Nucleic acid).
  • the isolated acyl-CoA: lysophospholipid acyltransferase molecule may contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences that naturally comprise the nucleic acid molecule flank in the genomic DNA of the cell from which the nucleic acid is derived.
  • nucleic acid molecules used in the method for example a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 or a part thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. It is also possible with the aid of comparative algorithms to identify, for example, a homologous sequence or homologous, conserved sequence regions at the DNA or amino acid level. These can be used as a hybridization probe in standard hybridization techniques (such as described in, for example, US Pat Sambrook and Russell, Molecular Cloning: A Laboratory Manual.
  • nucleic acid molecule comprising a complete sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 or a part thereof can be isolated by polymerase chain reaction using oligonucleotide primers based on this sequence or portions thereof (For example, a nucleic acid molecule comprising the complete sequence or a portion thereof can be isolated by polymerase chain reaction using oligonucleotide primers prepared on the basis of this same sequence).
  • mRNA can be isolated from cells (eg, by the guanidinium thiocyanate extraction method by Chirgwin et al. (1979) Biochemistry 18: 5294-5299 ) and cDNA by reverse transcriptase (eg, Moloney MLV reverse transcriptase, available from Gibco / BRL, Bethesda, MD, or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Russia, FL).
  • reverse transcriptase eg, Moloney MLV reverse transcriptase, available from Gibco / BRL, Bethesda, MD, or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Russia, FL.
  • Synthetic oligonucleotide primers for amplification by means of polymerase chain reaction can be based on one of the nucleic acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 or by means of in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6 create amino acid sequences shown.
  • a nucleic acid of the invention may be amplified using cDNA or alternatively genomic DNA as a template and suitable oligonucleotide primers according to standard PCR amplification techniques. The thus amplified nucleic acid can be cloned into a suitable vector and characterized by DNA sequence analysis.
  • Homologs of the acyl-CoA: lysophospholipid acyltransferase nucleic acid sequences having the sequence SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 means, for example, allelic variants having at least about 40 to 60%, preferably at least about 60 to 70 %, more preferably at least about 70 to 80%, 80 to 90% or 90 to 95%, and most preferably at least about 95%, 96%, 97%, 98%, 99% or more homology to any of the amino acid sequences set forth in SEQ ID NO : 1, SEQ ID NO: 3 or SEQ ID NO: 5 shown nucleotide sequences or their homologs, derivatives or analogs or parts thereof.
  • allelic variants comprise functional variants which can be obtained by deletion, insertion or substitution of nucleotides from / in the sequence shown in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, but the intention is that the enzyme activity of the resulting proteins is substantially retained.
  • Homologs of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 also mean, for example, bacterial, fungal and plant homologs, truncated sequences, single-stranded DNA or RNA of the coding and non-coding DNA sequence.
  • Homologs of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 also mean derivatives such as promoter variants.
  • the promoters upstream of the indicated nucleotide sequences may be modified by one or more nucleotide exchanges, insertion (s) and / or deletion (s), without, however, interfering with the functionality or activity of the promoters. It is also possible that the activity of the promoters is increased by modification of their sequence or that they are completely replaced by more active promoters, even from heterologous organisms.
  • nucleic acid molecules which code for proteins having acyl-CoA lysophospholipid acyltransferase activity, which are involved in the metabolism of lipids and fatty acids, PUFA cofactors and enzymes or in the transport of lipophilic compounds via membranes, are used in the process according to the invention for modulating the production of PUFAs in transgenic organisms beneficial in plants such as maize, wheat, rye, oats, triticale, rice, barley, soybean, peanut, cotton, linum species such as oil or fiber kidney, Brassica species such as oilseed rape, canola and turnip rape, pepper, sunflower, Borage, evening primrose and Tagetes, Solanacaen plants such as potato, tobacco, eggplant and tomato, Vicia species, pea, cassava, alfalfa, bush plants (coffee, cocoa, tea), Salix species, trees (oil palm, coconut) and perennials Grasses and forage crops, either directly (eg
  • PUFAs polyunsaturated fatty acids
  • the lipid synthesis can be divided into two sections: the synthesis of fatty acids and their attachment to sn-glycerol-3-phosphate and the addition or modification of a polar head group.
  • Common lipids used in membranes include phospholipids, glycolipids, sphingolipids and phosphoglycerides.
  • Fatty acid synthesis begins with the conversion of acetyl-CoA into malonyl-CoA by the acetyl-CoA carboxylase or into acetyl-ACP by the acetyl transacylase.
  • Precursors for the PUFA biosynthesis are, for example, oleic acid, linoleic acid and linolenic acid. These C18-carbon fatty acids must be elongated to C20 and C22 to give fatty acids of the eicosa and docosa chain type.
  • lysophospholipid acyltransferases used in the process advantageously in combination with desaturases such as the ⁇ -4-, ⁇ -5-, ⁇ -6- and ⁇ -8-desaturases and / or the ⁇ -5, ⁇ -6-, ⁇ -9 elongase can be arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid or docosahexaenoic acid, as well as various other long-chain PUFAs obtained, extracted and used for various purposes in food, feed, cosmetic or pharmaceutical applications.
  • the above-mentioned enzymes may preferably C 18 -, C 20 -, and / or C 22 fatty acids with at least two, advantageously at least three, four, five or six double bonds in the fatty acid molecule, preferably C 20 -, and / or C 22 - Fatty acids are advantageously produced with three, four or five double bonds in the fatty acid molecule.
  • the desaturation can be carried out before or after elongation of the corresponding fatty acid.
  • the products of desaturase activities and possible further desaturation and elongation result in preferred PUFAs having a higher degree of desaturation, including a further elongation of C 20 to C 22 fatty acids, to fatty acids such as ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, arachidonic acid, stearidonic acid, Eicosatetraenoic acid or eicosapentaenoic acid.
  • lyso-phospholipid acyltransferases in the process according to the invention are C 16 , C 18 , C 20 or C 22 fatty acids, such as, for example, palmitic acid, palmitoleic acid, linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, eicosatetraenoic acid or stearidonic acid.
  • Preferred substrates are linoleic acid, ⁇ -linolenic acid and / or ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid or arachidonic acid, eicosatetraenoic acid or eicosapentaenoic acid.
  • the C 18 , C 20 or C 22 fatty acids with at least two Double bonds in the fatty acid are obtained in the process according to the invention in the form of the free fatty acid or in the form of their esters, for example in the form of their glycerides.
  • glycolide is understood as meaning a glycerol (mono-, di- or triglyceride) esterified with one, two or three carboxylic acid residues.
  • glycolide is also meant a mixture of different glycerides.
  • the glyceride or glyceride mixture may contain other additives, e.g. contain free fatty acids, antioxidants, proteins, carbohydrates, vitamins and / or other substances.
  • a "glyceride” in the sense of the method according to the invention is also understood to mean derivatives derived from glycerol.
  • these also include glycerophospholipids and glyceroglycolipids. Examples include the glycerophospholipids lecithin (phosphatidylcholine), cardiolipin, phosphatidylglycerol, phosphatidylserine and Alkylacylglycerophospholipide called.
  • fatty acids must then be transported to various modification sites and incorporated into the triacylglycerol storage lipid.
  • Another important step in lipid synthesis is the transfer of fatty acids to the polar head groups, for example by glycerol-fatty acid acyltransferase (see Frentzen (1998) Lipid 100 (4-5): 161-166 ).
  • the PUFAs produced in the process comprise a group of molecules that are no longer able to (sufficiently) synthesize higher animals, and thus must (additionally) take up, although they are readily synthesized by other organisms such as bacteria.
  • acyl-CoA lysophospholipid acyltransferases
  • phospholipids are to be understood as meaning phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, and / or phosphatidylinositol, advantageously phosphatidylcholine.
  • the homology is over the entire amino acid or
  • the invention also comprises nucleic acid molecules which differ from one of the nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 (and parts thereof) due to the degenerate genetic code and thus the same acyl CoA: Lysophospholipid acyltransferase encode such as that encoded by the nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5.
  • acyl-CoA lysophospholipid acyltransferase nucleotide sequences shown in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, one skilled in the art will recognize that within a population, DNA sequence polymorphisms may exist that result in changes in the DNA sequence Amino acid sequences of the acyl-CoA: lysophospholipid acyltransferases can result. These genetic polymorphisms in the acyl-CoA: lysophospholipid acyltransferase gene may exist due to natural variation between individuals within a population.
  • Nucleic acid molecules useful in the method of the present invention can be isolated based on their homology to the acyl-CoA: lysophospholipid acyltransferase nucleic acids disclosed herein using the sequences or a portion thereof as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
  • isolated nucleic acid molecules can be used which are at least 15 nucleotides long and which hybridize under stringent conditions with the nucleic acid molecules which comprise a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5.
  • Nucleic acids of at least 25, 50, 100, 250 or more nucleotides may also be used.
  • hybridized under stringent conditions is intended to describe hybridization and washing conditions under which nucleotide sequences that are at least 60% homologous to one another usually remain hybridized to one another.
  • the conditions are preferably such that sequences which are at least about 65%, preferably at least about 70%, and more preferably at least about 75% or more homologous, are usually hybridized to each other.
  • stringent conditions are known in the art and can be in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. , Find.
  • a preferred, non-limiting example of stringent hybridization conditions are hybridizations in 6x sodium chloride / sodium citrate (SSC) at about 45 ° C, followed by one or more washes in 0.2x SSC, 0.1% SDS at 50 to 65 ° C. It is known to the person skilled in the art that these hybridization conditions may differ with regard to the temperature and the concentration of the buffer, depending on the type of nucleic acid and, for example, whether organic solvents are present. For example, the temperature is below "standard hybridization conditions" depending on the type of Nucleic acid between 42 ° C and 58 ° C in aqueous buffer at a concentration of 0.1 to 5 x SSC (pH 7.2).
  • the temperature is about 42 ° C under standard conditions.
  • the hybridization conditions for DNA: DNA hybrids are, for example, 0.1 x SSC and 20 ° C to 45 ° C, preferably between 30 ° C and 45 ° C.
  • the hybridization conditions for DNA: RNA hybrids are, for example, 0.1 x SSC and 30 ° C to 55 ° C, preferably between 45 ° C and 55 ° C.
  • the sequences are written among themselves for optimal comparison (eg, gaps can be inserted into the sequence of one protein or one nucleic acid to create an optimal alignment with the other protein or nucleic acid).
  • the amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared.
  • amino acid or nucleic acid "homology” as used herein corresponds to amino acid or nucleic acid “identity”).
  • the programs or algorithms used are given above.
  • An isolated nucleic acid molecule encoding an acyl-CoA: lysophospholipid acyltransferase homologous to a protein sequence of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6 may be prepared by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 are generated so that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into any of the sequences of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative amino acid substitutions are made on one or more of the predicted nonessential amino acid residues.
  • an amino acid residue is replaced with an amino acid residue having a similar side chain.
  • families of amino acid residues have been defined with similar side chains.
  • amino acids with basic side chains eg, lysine, arginine, histidine
  • acidic side chains eg, aspartic acid, glutamic acid
  • uncharged polar side chains eg, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • nonpolar side chains eg, alanine , Valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta-branched side chains eg, threonine, valine, isoleucine
  • aromatic side chains eg, tyrosine, phenylalanine, tryptophan, histidine
  • a predicted nonessential amino acid residue in an acyl-CoA: lysophospholipid acyltransferase thus becomes preferably replaced by another amino acid residue from the same side chain family.
  • the mutations may be introduced randomly over all or part of the acyl-CoA: lysophospholipid acyltransferase-encoding sequence, for example, by saturation mutagenesis, and the resulting mutants may be prepared according to the acyl-CoA: lysophospholipid-acyltransferase- Activity to identify mutants that have retained the acyl-CoA: lyso-phospholipid acyltransferase activity.
  • the encoded protein can be recombinantly expressed and the activity of the protein can be determined, for example, using the assays described herein.
  • Cloning methods such as, for example, restriction cleavages, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linkage of DNA fragments, transformation of Escherichia coli - and Yeast cells, bacterial growth and sequence analysis of recombinant DNA were performed as described in Sambrook and Russell (2001) (Cold Spring Harbor Laboratory Press: ISBN 0-87969-309-6 ) or Kaiser, Michaelis and Mitchell (1994) "Methods in Yeast Genetics” (Cold Spring Harbor Laboratory Press: ISBN 0-87969-451-3 ).
  • DNA modifying enzymes and molecular biology kits were purchased from AGS (Heidelberg), Amersham (Brunswick), Biometra (Göttingen), Roche (Mannheim), Genomed (Bad Oeynhausen), New England Biolabs (Schwalbach / Taunus), Novagen (Madison, Wisconsin, USA), Perkin-Elmer (Weiterstadt), Pharmacia (Freiburg), Qiagen (Hilden) and Stratagene (Amsterdam, The Netherlands). Unless otherwise stated, they were used according to the manufacturer's instructions.
  • the amplification of the OtLPCAT DNA was carried out in each case with 1 ⁇ l of thawed cells, 200 ⁇ M dNTPs, 2.5 U Taq polymerase and 100 pmol of each primer in a total volume of 50 ⁇ l.
  • the conditions for the PCR were as follows: first denaturation at 95 ° C for 5 minutes, followed by 30 cycles at 94 ° C for 30 seconds, 55 ° C for 1 minute and 72 ° C for 2 minutes and a final extension step at 72 ° C for 10 minutes.
  • the corresponding primer pairs were selected to express the yeast consensus sequence for highly efficient translation (FIG. Kozak (1986) Cell 44: 283-292 ) next to the start codon.
  • the amplification of the OtLPCAT was carried out in each case with 1 .mu.l cDNA, 200 .mu.M dNTPs, 2.5 U Advantage polymerase and 100 pmol of each primer in a total volume of 50 .mu.l.
  • the conditions for the PCR were as follows: first denaturation at 95 ° C for 5 minutes, followed by 30 cycles at 94 ° C for 30 seconds, 55 ° C for 1 minute and 72 ° C for 2 minutes and a final extension step at 72 ° C for 10 minutes.
  • the PCR products were incubated for 30 min at 21 ° C with the yeast expression vector pYES2.1-TOPO (Invitrogen) according to the manufacturer.
  • the PCR product is ligated by a T-overhang and activity of a topoisomerase (Invitrogen) in the vector.
  • transformation of E. coli DH5 ⁇ cells was then carried out.
  • Corresponding clones were identified by PCR, the plasmid DNA isolated using Qiagen DNAeasy kit and verified by sequencing.
  • the sequence of the resulting plasmid pYES2.1-OtLPCAT is shown in SEQ ID no. 7 indicated.
  • the correct sequence was then transformed into the Saccharomyces strain INVSc1 (Invitrogen) by electroporation (1500V).
  • the empty vector pYES2.1 was transformed in parallel. Subsequently, the yeasts were plated on complete minimal medium without uracil with 2% glucose. Cells which were capable of growth in the medium without uracil contained the corresponding plasmids pYES2.1 or pYES2.1-OtLPCAT. After selection, two transformants were selected for further functional expression.
  • pSUN300 is a derivative of the plasmid pPZP ( Hajdukiewicz, P. et al. (1994) Plant Mol. Biol. 25: 989-994 ).
  • pSUN-USP was generated from pSUN300 by inserting into pSUN300 a USP promoter as Eco RI fragment.
  • the USP promoter corresponds to nucleotides 1-684 (Genbank Accession X56240), with part of the non-coding region of the USP gene contained in the promoter.
  • the 684 base pair promoter fragment was amplified using a commercially available T7 standard primer (Stratagene) and a synthesized primer amplified via a PCR reaction according to standard methods.
  • the PCR fragment was rescored with EcoRI / SalI and inserted into the vector pSUN300 with OCS terminator.
  • the polyadenylation signal is that of the octopine synthase gene from the A. tumefaciens Ti plasmid (ocs terminator, Genbank Accession V00088) ( De Greve, H. et al. (1982) J. Mol. Appl. Genet. 1 (6): 499-511 ).
  • the result was the plasmid with the name pSUN-USP.
  • the construct was used to transform Arabidopsis thaliana , rape, tobacco and linseed.
  • the PCR products were incubated for 16 h at 37 ° C with the restriction enzyme NotI.
  • the plant expression vector pSUN300-USP was incubated in the same way. Subsequently, the PCR products and the 7624 bp vector were separated by agarose gel electrophoresis and the corresponding DNA fragments were excised. The purification of the DNA fragments was carried out using Qiagen Gel Purification Kit according to the manufacturer. Subsequently, vector and PCR products were ligated. The Rapid Ligation Kit from Roche was used for this purpose. The resulting plasmid pSUN-OtLPCAT was verified by sequencing.
  • OtLPCAT The activity of OtLPCAT could be determined after expression of OtLPCAT in yeasts and feeding of various fatty acids ( Fig. 2 ).
  • the double construct pESCLeu-PpD6-PSEI was also prepared, which contains the open reading frames of a ⁇ 6-desaturase (PpD6) and a ⁇ 6-elongase (PSE1) from Physcomitrella patens ( please refer DE 102 19 203 ) and transformed together with either the empty vector pYES2.1 or the vector pYES2.1-OtLPCAT.
  • the cloning of the construct pESCLeu-PpD6-PSE1 can be the WO 2004/076617 are taken, the contents of which are hereby incorporated by reference.
  • Analytical techniques for determining the fatty acid composition of organisms are known to those of skill in the art and include spectroscopy, thin-layer chromatography, staining methods of various types, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example Ullman (1985) Encyclopedia of Industrial Chemistry, Vol. A2, pp. 89-90 and pp. 443-613, VCH Weinheim ; Fallon, A. et al. (1987) "Applications of HPLC in Biochemistry” in: Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 17 ; Rehm et al. (1993) "Product recovery and purification” in: Biotechnology, Vol. 3, Chapter III, pp.
  • the yeast cells from the major cultures were harvested by centrifugation (100 xg, 10 min, 20 ° C) and washed with 100 mM NaHCO 3 , pH 8.0 to remove residual medium and fatty acids.
  • fatty acid methyl esters FAMEs
  • FAMEs fatty acid methyl esters
  • the organic phases were washed once each with 2 ml of 100 mM NaHCO 3 , pH 8.0 and 2 ml of distilled water. washed. Subsequently, the PE phases were dried with Na 2 SO 4 , evaporated under argon and taken up in 100 ⁇ l of PE.
  • the samples were separated on a DB-23 capillary column (30 m, 0.25 mm, 0.25 ⁇ m, Agilent) in a Hewlett-Packard 6850 gas chromatograph with flame ionization detector.
  • the conditions for the GLC analysis were as follows: The oven temperature was programmed from 50 ° C to 250 ° C at a rate of 5 ° C / min and finally at 250 ° C (hold) for 10 min.
  • Fig. 2A shows the conversion of the fed fatty acid 18: 2 ⁇ 9,12 to 20: 3 ⁇ 8,11,14 by yeasts that had been transformed with the plasmids pESCLeu-PpD6-PSEl and pYES2.1.
  • Fig. 2B shows the conversion into yeasts which additionally contain the plasmid pYES2.1-OtLPCAT in addition to the plasmid pESCLeu-PpD6-PSE1.
  • the fed substrate was abundant in all transgenic yeasts. Both transgenic yeasts showed a synthesis of 18: 3 ⁇ 6,9,12 and 20: 3 ⁇ 8,11,14 , the products of the ⁇ -6-desaturase and ⁇ -6 elongase reactions. This means that the genes PpD6 and PSE1 could be functionally expressed.
  • the associated genomic DNAs were amplified by PCR.
  • the corresponding primer pairs were selected such that they contain the first 20 nucleotides at the 5 'end and the last 20 nucleotides at the 3' end (including stop codon) and at the 5 'end additionally the yeast consensus sequence for highly efficient translation ( Kozak (1986) Cell 44: 283-292 ) carried.
  • the amplification of the MsLPCAT DNAs was carried out in each case with 1 ⁇ l of thawed cells, 200 ⁇ M dNTPs, 2.5 U Taq polymerase and 100 pmol of each primer in a total volume of 50 ⁇ l.
  • the conditions for the PCR were as follows: first denaturation at 95 ° C for 5 minutes followed by 30 cycles at 94 ° C for 30 seconds, 55 ° C for 1 minute and 72 ° C for 2 minutes and a final extension step at 72 ° C for 10 minutes.
  • the corresponding primer pairs were selected to express the yeast consensus sequence for highly efficient translation (FIG. Kozak (1986) Cell 44: 283-292 ) next to the start codon.
  • the amplification of the MsLPCATs was carried out in each case with 1 ⁇ L of cDNA, 200 ⁇ M dNTPs, 2.5 U Advantage polymerase and 100 pmol of each primer in a total volume of 50 ⁇ l.
  • the conditions for the PCR were as follows: first denaturation at 95 ° C for 5 minutes followed by 30 cycles at 94 ° C for 30 seconds, 55 ° C for 1 minute and 72 ° C for 2 minutes and a final extension step at 72 ° C for 10 minutes.
  • PCR products were incubated for 30 min at 21 ° C with the yeast expression vector pYES2.1-TOPO (Invitrogen) according to the manufacturer.
  • the PCR product is ligated by a T-overhang and activity of a topoisomerase (Invitrogen) in the vector.
  • transformation of E. coli DH5 ⁇ cells was then carried out.
  • Corresponding clones were identified by PCR, the plasmid DNA isolated using Qiagen DNAeasy kit and verified by sequencing.
  • the sequences of the resulting plasmids pYES2.1-MsLPCAT112 and pYES2.1-MsLPCAT118 are shown in SEQ ID Nos. 8 or 9 indicated.
  • the correct sequence was then translated into the Saccharomyces strain INVSc1 (Invitrogen) Electroporation (1500 V) transformed.
  • the empty vector pYES2.1 was transformed in parallel.
  • the yeasts were plated on complete minimal medium without uracil with 2% glucose. Cells that were capable of growth in the medium without uracil contained the corresponding plasmids pYES2.1, pYES2.1-MsLPCAT112 or pYES2.1-MsLPCAT118. After selection, two transformants were selected for further functional expression.
  • the PCR products were incubated for 16 h at 37 ° C with the restriction enzyme Not I.
  • the plant expression vector pSUN300-USP was incubated in the same way. Subsequently, the PCR products and the 7624 bp vector were separated by agarose gel electrophoresis and the corresponding DNA fragments were excised. The purification of the DNA fragments was carried out using Qiagen Gel Purification Kit according to the manufacturer. Subsequently, vector and PCR products were ligated. The Rapid Ligation Kit from Roche was used for this purpose. The resulting plasmids pSUN-MsLPCAT112 and pSUN-MsLPCAT118 were verified by sequencing.
  • the activity of the MsLPCATs could be determined after expression of the MsLPCATs in yeasts and feeding of various fatty acids ( Fig. 3A , B and C).
  • the construct pESCLeu-PpD6-PSE1 was introduced into the yeast together with either the empty vector pYES2.1 or the plasmid pYES2.1-MsLPCAT112 or pYES2.1-MsLPCAT118.
  • FIG. 3A shows the conversion of the fed fatty acid 18: 2 ⁇ 9,12 to 20: 3 ⁇ 8,11,14 by yeasts that had been transformed with the plasmid pESCLeu-PpD6-PSE1 and pYES2.1.
  • FIG. 3B shows the conversion into yeasts which additionally contain the plasmid pYES2.1-MsLPCAT112 in addition to the plasmid pESCLeu-PpD6-PSE1.
  • FIG. 3C describes the fatty acid spectrum of yeasts transformed with the plasmids pESCLeu-PpD6-PSE1 and pYES2.1-MsLPCAT118 were.
  • the fed substrate linoleic acid (18: 2) was detectable in large quantities in all transgenic yeasts. All transgenic yeasts displayed a synthesis of 18: 3 ⁇ 6,9,12 and 20: 3 ⁇ 8,11,14 , the products of ⁇ 6 -desaturase and ⁇ 6 -elongase reactions. This means that the genes PpD6 and Pse1 could be expressed functionally.
  • LCPUFA-specific acyltransferases in transgenic plants is advantageous in order to increase the LCPUFA content in these plants.
  • the acyltransferase cDNAs according to the invention were cloned into binary vectors (see Examples 4 and 8) and transferred via Agrobacterium-mediated DNA transfer into Arabidopsis thaliana, Brassica napus and Linum usitatissimum .
  • the expression of the acyltransferase cDNA was under the control of the seed-specific USP promoter (construction of the binary plasmid pSUN300-USP see Example 4).
  • transgenic plants which already express the desaturases and elongases necessary for the synthesis of LCPUFAs and produce small amounts of these LCPUFAs.
  • Such plants are for example those in DE 102 19 203 which contain functional genes for ⁇ -6-desaturase, ⁇ 6-elongase and ⁇ 5-desaturase and produce small amounts of ARA and EPA.
  • acyltransferase genes in Arabidopsis, tobacco, rapeseed and linseed transgenic plants was examined by Northern blot analysis. Selected plants were examined for their content of PUFAs in seed oil.
  • Agrobacterium-mediated plant transformation can be carried out using standard transformation and regeneration techniques ( Gelvin, Stanton B., Schilperoort, Robert A., Plant Molecular Biology Manual, 2nd Ed., Dordrecht: Kluwer Academic Publ., 1995, in Sect., Ringbuc Central Signature: BT11-P ISBN 0-7923-2731-4 ; Glick, Bernard R., Thompson, John E., Methods in Plant Molecular Biology and Biotechnology, B. Raton: CRC Press, 1993, 360 p., ISBN 0-8493-5164-2 ).
  • rapeseed can be transformed by cotyledon or hypocotyl transformation ( Moloney et al. (1989) Plant Cell Report 8: 238-242 ; De Block et al. (1989) Plant Physiol. 91: 694-701 ).
  • the use of antibiotics for Agrobacterium and plant selection depends on the binary vector and Agrobacterium strain used for the transformation. Rapeseed selection is usually carried out using kanamycin as a selectable plant marker.
  • the Agrobacterium-mediated gene transfer in flax Linum usitatissimum
  • Plant Cell Report 13: 282-285 perform the described technique.
  • soy can be done using, for example, an in EP-A-0424047 (Pioneer Hi-Bred International) or in EP-A-0397687 . US 5,376,543 . US 5,169,770 (University Toledo) described technique. Plant transformation using particle bombardment, polyethylene glycol-mediated DNA uptake or via the silicon carbonate fiber technique is described, for example by Freeling and Walbot "The maize handbook” (1993) ISBN 3-540-97826-7, Springer publishing house New York ,
  • TAG fatty acids or triacylglycerol
  • FAME fatty acid methyl ester
  • GC-MS gas-liquid chromatography-mass spectrometry
  • TLC thin layer chromatography
  • the plant material to be analyzed may be broken up either by sonication, milling in the glass mill, liquid nitrogen and milling or by other applicable methods. The material is then centrifuged after rupture. The sediment is then distilled in aqua. re-suspended, heated at 100 ° C for 10 min, cooled on ice and recentrifuged, followed by extraction into 0.5 M sulfuric acid in methanol with 2% dimethoxypropane for 1 h at 90 ° C resulting in hydrolyzed oil and lipid compounds. which give transmethylated lipids.
  • fatty acid methyl esters can then be extracted into petroleum ether and finally subjected to GC analysis using a capillary column (Chrompack, WCOT Fused Silica, CP-Wax-52 CB, 25 microm, 0.32 mm) at a temperature gradient between 170 ° C and 240 ° C for 20 min and 5 min at 240 ° C are subjected.
  • the identity of the resulting fatty acid methyl esters can be defined using standards available from commercial sources (i.e., Sigma).
  • the total fatty acids were extracted from plant seeds and analyzed by gas chromatography.
  • the seeds were taken up with 1% sodium methanolate in methanol and incubated for 20 min at RT (about 22 ° C). It was then washed with NaCl solution and taken up the FAME in 0.3 ml of heptane.
  • the samples were separated on a ZEBRON ZB Wax capillary column (30 m, 0.32 mm, 0.25 micron, Phenomenex) in a Hewlett Packard 6850 gas chromatograph with a flame ionization detector.
  • the oven temperature was maintained from 70 ° C (hold for 1 min) to 200 ° C at a rate of 20 ° C / min, then to 250 ° C (hold for 5 min) at a rate of 5 ° C / min, and finally to 260 ° C programmed at a rate of 5 ° C / min.
  • Nitrogen was used as the carrier gas (4.5 ml / min at 70 ° C).
  • the fatty acids were identified by comparison with retention times of FAME standards (SIGMA).
  • acyl-CoA lyso-phospholipid acyltranserase as in Fig. 4 derived derived.
  • the biosynthetic pathway of the LCPUFAS is thus as follows:
  • Desaturases catalyze the introduction of double bonds into lipid-coupled fatty acids ( sn2- acyl-phosphatidylcholine), while the elongases exclusively catalyze the elongation of coenzyme A-esterified fatty acids (acyl-CoAs).
  • acyl-CoAs coenzyme A-esterified fatty acids
  • the alternating action of desaturases and elongases requires a constant exchange of acyl substrates between phospholipids and the acyl-CoA pool and thus the existence of an additional activity which converts the acyl substrates into the respectively required substrate form, ie lipids (for Desaturases) or CoA thioesters (for elongases).
  • This exchange between acyl-CoA pool and phospholipids is facilitated by LCPUFA-specific acyl-CoA: lyso-phospholipid acyltranserases.
  • One embodiment of the invention is an isolated nucleic acid sequence, wherein the sequence is derived from a eukaryote.
  • Another embodiment of the invention is an amino acid sequence encoded by one of the above isolated nucleic acid sequences.
  • Another embodiment of the invention relates to a gene construct containing one of the above isolated nucleic acid sequences, wherein the nucleic acid is operably linked to one or more regulatory signals.
  • acyl-CoA dehydrogenase s
  • a further embodiment of the invention is a gene construct, characterized in that the nucleic acid construct contains additional biosynthesis genes of the fatty acid or lipid metabolism selected from the group of ⁇ -4-desaturase, ⁇ -5-desaturase, ⁇ -6-desaturase, ⁇ -8-desaturase, ⁇ -9-desaturase, ⁇ -12-desaturase, ⁇ -5 elongase, ⁇ -6 elongase or ⁇ -9 elongase genes.
  • a further embodiment of the invention relates to a vector containing one of the abovementioned nucleic acids or gene constructs.
  • One embodiment of the invention is a transgenic non-human organism containing one of the above-mentioned nucleic acids, gene constructs or vectors.
  • the transgenic non-human organism is a microorganism, a non-human animal or a plant
  • the transgenic non-human organism is a plant.
  • the method is characterized in that, in addition to the nucleic acid sequences mentioned under step a), further nucleic acid sequences are introduced into the organism selected for polypeptides of the fatty acid or lipid metabolism selected from the group consisting of acyl-CoA dehydrogenase ( n), acyl-ACP [acyl carrier protein] desaturase (s), acyl-ACP thioesterase (s), fatty acyl transferase (s), fatty acid synthase (s), fatty acid hydroxylase (s), Acetyl coenzyme A carboxylase (s), acyl coenzyme A oxidase (s), fatty acid desaturase (s), fatty acid acetylenases, lipoxygenases, Triacylglycerol lipases, allene oxide synthases, hydroperoxide lyases or fatty acid elongase (s) encode.
  • acyl-CoA dehydrogenase n
  • a further embodiment of the invention is a method, characterized in that, in addition to the abovementioned nucleic acid sequences, further nucleic acid sequences are introduced into the organism which, for polypeptides, are selected from the group consisting of ⁇ -4-desaturases, ⁇ -5-desaturases, ⁇ - 6-desaturases, ⁇ -8-desaturases, ⁇ -9-desaturases, ⁇ -12-desaturases, ⁇ -5-elongases, ⁇ -6-elongase or ⁇ -9-elongases.
  • a further embodiment of the invention relates to a process, characterized in that C 16 , C 18 , C 20 or C 22 fatty acids are used as substrate of the acyl-CoA: lysophospholipid acyltransferases.
  • Another embodiment of the invention is a method, characterized in that the polyunsaturated fatty acids are isolated from the organism in the form of an oil, lipid or a free fatty acid.
  • a further embodiment of the invention is a process, characterized in that the polyunsaturated fatty acids produced in the process are C 18 , C 20 or C 22 fatty acids having at least two double bonds in the molecule.
  • a further embodiment of the invention relates to a method, characterized in that in the method a polyunsaturated fatty acid selected from the group consisting of dihomo- ⁇ -linolenic acid, arachidonic acid, Eisosapentaenklare, docosapentaenoic acid and docosahexaenoic acid is prepared.
  • Another embodiment of the present invention is a method, characterized in that the organism is a microorganism, a non-human animal or a plant.
  • Another preferred embodiment of the invention is a method, characterized in that the organism is a transgenic plant.
  • the transgenic plant is an oil crop.
  • Another part of the invention relates to oil, lipids or fatty acids or a fraction thereof, prepared by one of the abovementioned processes according to the invention.
  • Another part of the invention relates to an oil, lipid or fatty acid composition
  • an oil, lipid or fatty acid composition comprising polyunsaturated fatty acids prepared by one of the above-mentioned methods according to the invention and derived from transgenic plants.
  • Another part of the invention relates to the use of oil, lipids or fatty acids prepared by one of the above-mentioned methods according to the invention or one of the abovementioned oil, lipid or fatty acid compositions in feed, foodstuffs, cosmetics or pharmaceuticals.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
EP09179432.1A 2004-12-23 2005-12-20 Procédé de production d'acides gras à longues chaînes multi-insaturés dans des organismes transgéniques Not-in-force EP2180046B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004062294A DE102004062294A1 (de) 2004-12-23 2004-12-23 Verfahren zur Herstellung von mehrfach ungesättigten langkettigen Fettsäuren in transgenen Organismen
EP05821795A EP1831358A2 (fr) 2004-12-23 2005-12-20 Procede de production d'acides gras a longues chaines multi-insatures dans des organismes transgeniques

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP05821795.1 Division 2005-12-20
EP05821795A Division EP1831358A2 (fr) 2004-12-23 2005-12-20 Procede de production d'acides gras a longues chaines multi-insatures dans des organismes transgeniques

Publications (2)

Publication Number Publication Date
EP2180046A1 true EP2180046A1 (fr) 2010-04-28
EP2180046B1 EP2180046B1 (fr) 2014-06-25

Family

ID=36590482

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05821795A Withdrawn EP1831358A2 (fr) 2004-12-23 2005-12-20 Procede de production d'acides gras a longues chaines multi-insatures dans des organismes transgeniques
EP09179432.1A Not-in-force EP2180046B1 (fr) 2004-12-23 2005-12-20 Procédé de production d'acides gras à longues chaînes multi-insaturés dans des organismes transgéniques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05821795A Withdrawn EP1831358A2 (fr) 2004-12-23 2005-12-20 Procede de production d'acides gras a longues chaines multi-insatures dans des organismes transgeniques

Country Status (12)

Country Link
US (1) US7871804B2 (fr)
EP (2) EP1831358A2 (fr)
CN (1) CN101072869A (fr)
AU (1) AU2005321344A1 (fr)
BR (1) BRPI0519254A2 (fr)
CA (1) CA2591599A1 (fr)
DE (1) DE102004062294A1 (fr)
IL (1) IL183103A0 (fr)
MX (1) MX2007006535A (fr)
NO (1) NO20072663L (fr)
RU (1) RU2007127798A (fr)
WO (1) WO2006069936A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108866181A (zh) * 2018-07-18 2018-11-23 北京泱深生物信息技术有限公司 Mboat1基因在子痫前期中的应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056110C (fr) 2004-04-22 2020-07-14 Surinder Pal Singh Synthese d'acides gras polyinsatures a chaine longue par des cellules de recombinaison
CN103451246B (zh) 2004-04-22 2018-02-16 联邦科学技术研究组织 用重组细胞合成长链多不饱和脂肪酸
US7879591B2 (en) 2004-11-04 2011-02-01 E.I. Du Pont De Nemours And Company High eicosapentaenoic acid producing strains of Yarrowia lipolytica
BRPI0716075A2 (pt) 2006-08-29 2013-08-06 Commw Scient Ind Res Org sÍntese de Ácidos graxos
BR122021003836B1 (pt) 2008-11-18 2022-02-01 Commonwealth Scientific And Industrial Research Organisation Polinucleotídeo isolado e/ou exógeno que não ocorre de forma natural, vetor e método para produzir óleo contendo ácidos graxos insaturados
EP2358862B1 (fr) * 2008-12-18 2017-08-02 E. I. du Pont de Nemours and Company Réduction des sous-produits malonates formés dans un procédé de fermentation
WO2010118477A1 (fr) 2009-04-17 2010-10-21 Molecular Plant Breeding Nominees Ltd Promoteur végétal apte à agir dans l'endosperme et ses utilisations
US8399226B2 (en) 2009-06-16 2013-03-19 E I Du Pont De Nemours And Company High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica
DK2442666T3 (da) 2009-06-16 2015-07-13 Du Pont Olier med højt indhold af eicosapentaensyre fra forbedrede og optimerede stammer af yarrowia lipolytica
AU2010260227B2 (en) 2009-06-16 2015-01-29 E. I. Du Pont De Nemours And Company Improvement of long chain omega-3 and omega-6 polyunsaturated fatty acid biosynthesis by expression of acyl-CoA lysophospholipid acyltransferases
JP5893555B2 (ja) 2009-06-16 2016-03-23 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ エイコサペンタエン酸を高産生するよう改良されたヤロウイア・リポリティカ（Ｙａｒｒｏｗｉａ ｌｉｐｏｌｙｔｉｃａ）最適化株
EP3121283B1 (fr) 2009-08-31 2018-05-02 BASF Plant Science Company GmbH Molécules d'acide nucléique régulatrices pour l'amélioration de l'expression de gènes spécifiques des semences dans des plantes de promotion de la synthèse d'acides gras polyinsaturés améliorée
JP2013535987A (ja) 2010-08-26 2013-09-19 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 高レベルのエイコサペンタエン酸生産のための組換え微生物宿主細胞
US8790901B2 (en) 2011-12-14 2014-07-29 Pronutria, Inc. Microorganisms and methods for producing unsaturated fatty acids
DE102012200003B4 (de) 2012-01-02 2015-04-30 Ford Global Technologies, Llc Flüssigkeitsgekühlte Brennkraftmaschine und Verfahren zum Betreiben einer derartigen Brennkraftmaschine
US9096834B2 (en) 2012-02-24 2015-08-04 Exxonmobil Research And Engineering Company Recombinant microorganisms comprising thioesterase and lysophosphatidic acid acyltransferase genes for fatty acid production
US9181568B2 (en) * 2012-04-23 2015-11-10 Exxonmobil Research And Engineering Company Cell systems and methods for improving fatty acid synthesis by expression of dehydrogenases
HUE033766T2 (en) 2012-06-15 2018-01-29 Commw Scient Ind Res Org Preparation of long chain polyunsaturated fatty acids in plant cells
EP2861728B1 (fr) 2012-06-19 2017-12-27 E. I. du Pont de Nemours and Company Production améliorée d'acides gras polyinsaturés par coexpression d'acyl-coa: lysophosphatidylcholine acyltransférases et de phospholipide: diacylglycérol acyltransférases
SG11201501013PA (en) 2012-08-10 2015-04-29 Opx Biotechnologies Inc Microorganisms and methods for the production of fatty acids and fatty acid derived products
DK2935601T3 (en) * 2012-12-21 2018-06-18 Du Pont RECOMBINANT MICROBELL CELLS PRODUCING AT LEAST 28% EICOSAPENTAIC ACID AS DRY WEIGHT
US20150119601A1 (en) 2013-03-15 2015-04-30 Opx Biotechnologies, Inc. Monofunctional mcr + 3-hp dehydrogenase
US11408013B2 (en) 2013-07-19 2022-08-09 Cargill, Incorporated Microorganisms and methods for the production of fatty acids and fatty acid derived products
WO2015010103A2 (fr) 2013-07-19 2015-01-22 Opx Biotechnologies, Inc. Micro-organismes et procédés pour la production d'acides gras et de produits dérivés d'acides gras
CA3241340A1 (fr) 2013-12-18 2015-06-25 Grains Research And Development Corporation Lipides comprenant des acides gras polyinsatures a longue chaine
SG11201610596PA (en) 2014-06-27 2017-01-27 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid
EP2993228B1 (fr) 2014-09-02 2019-10-09 Cargill, Incorporated Production d'esters d'acides gras
JP2020506702A (ja) 2017-02-02 2020-03-05 カーギル インコーポレイテッド Ｃ６−ｃ１０脂肪酸誘導体を生成する遺伝子組み換え細胞
WO2019055326A1 (fr) * 2017-09-12 2019-03-21 Biocapital Holdings, Llc Dispositifs biologiques et leurs procédés d'utilisation pour produire des caroténoïdes
CN113502295B (zh) * 2021-06-09 2022-06-07 西北农林科技大学 TmLPCAT基因用于提高三酰甘油sn-2位超长链脂肪酸含量的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018889A2 (fr) * 1998-09-25 2000-04-06 Calgene Llc Nouvelles acyltransferases vegetales
FR2785911A1 (fr) * 1998-11-18 2000-05-19 Agronomique Inst Nat Rech Gene codant pour une acyltransferase de colza, et ses utilisations
US20040034888A1 (en) * 1999-05-06 2004-02-19 Jingdong Liu Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2004076617A2 (fr) 2003-02-27 2004-09-10 Basf Plant Science Gmbh Procede de production d'acides gras polyinsatures
WO2004087902A2 (fr) * 2003-03-31 2004-10-14 University Of Bristol Nouvelles acyltransferases vegetales specifiques pour acides gras a longue chaine polyinsatures

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018889A2 (fr) * 1998-09-25 2000-04-06 Calgene Llc Nouvelles acyltransferases vegetales
FR2785911A1 (fr) * 1998-11-18 2000-05-19 Agronomique Inst Nat Rech Gene codant pour une acyltransferase de colza, et ses utilisations
US20040034888A1 (en) * 1999-05-06 2004-02-19 Jingdong Liu Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2004076617A2 (fr) 2003-02-27 2004-09-10 Basf Plant Science Gmbh Procede de production d'acides gras polyinsatures
WO2004087902A2 (fr) * 2003-03-31 2004-10-14 University Of Bristol Nouvelles acyltransferases vegetales specifiques pour acides gras a longue chaine polyinsatures

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAHLQVIST A ET AL: "Phospholipid:diacylglycerol acyltransferase: an enzyme that catalyses the acyl-coA-independent formation of triacylglycerol in yeast and plants", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 12, 6 June 2000 (2000-06-06), pages 6487 - 6492, XP002235601, ISSN: 0027-8424 *
DATABASE UniProt [online] 6 December 2005 (2005-12-06), "Lysophosphatidic acid acyltransferase, putative.", XP002387919, retrieved from EBI Database accession no. Q337H3 *
DOMERGUE F ET AL: "Relief for fish stocks: oceanic fatty acids in transgenic oilseeds", TRENDS IN PLANT SCIENCE, ELSEVIER SCIENCE, OXFORD, GB, vol. 10, no. 3, March 2005 (2005-03-01), pages 112 - 116, XP004776171, ISSN: 1360-1385 *
YAMASHITA A ET AL: "ATP-independent fatty acyl-coenzyme A synthesis from phospholipid: coenzyme A-dependent transacylation activity toward lysophosphatidic acid catalyzed by acyl-coenzyme A:lysophosphatidic acid acyltransferase.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 20 JUL 2001, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 26745 - 26752, XP002387917, ISSN: 0021-9258 *
YAMASHITA ATSUSHI ET AL: "Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells", JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 122, no. 1, 1997, pages 1 - 16, XP002387916, ISSN: 0021-924X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108866181A (zh) * 2018-07-18 2018-11-23 北京泱深生物信息技术有限公司 Mboat1基因在子痫前期中的应用
CN108866181B (zh) * 2018-07-18 2020-06-30 青岛泱深生物医药有限公司 Mboat1基因在子痫前期中的应用

Also Published As

Publication number Publication date
RU2007127798A (ru) 2009-01-27
AU2005321344A1 (en) 2006-07-06
NO20072663L (no) 2007-09-06
MX2007006535A (es) 2007-07-25
US7871804B2 (en) 2011-01-18
EP2180046B1 (fr) 2014-06-25
CA2591599A1 (fr) 2006-07-06
CN101072869A (zh) 2007-11-14
DE102004062294A1 (de) 2006-07-06
WO2006069936A2 (fr) 2006-07-06
IL183103A0 (en) 2007-09-20
US20090094707A1 (en) 2009-04-09
WO2006069936A3 (fr) 2007-03-22
BRPI0519254A2 (pt) 2009-01-06
EP1831358A2 (fr) 2007-09-12

Similar Documents

Publication Publication Date Title
EP2180046B1 (fr) Procédé de production d'acides gras à longues chaînes multi-insaturés dans des organismes transgéniques
EP1599582B1 (fr) Procede de production d'acides gras polyinsatures
EP2365063B1 (fr) Nouvelles acyltransférases végétales spécifiques aux acides gras insaturés multiples à chaîne longue
US7893320B2 (en) Method for producing multiple unsaturated fatty acids in plants
WO2008009600A1 (fr) Procédé de fabrication d'acide arachidonique et/ou d'acide eicosapentaénoïque dans des plantes
WO2002057465A2 (fr) Procede de production d'acides gras polyinsatures, nouveaux genes biosynthetiques et nouvelles constructions d'expression vegetales
DE102004017518A1 (de) Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091216

AC Divisional application: reference to earlier application

Ref document number: 1831358

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20110623

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130618

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131018

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140128

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1831358

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 674744

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502005014422

Country of ref document: DE

Effective date: 20140814

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140926

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141027

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20141130

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141025

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502005014422

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150326

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502005014422

Country of ref document: DE

Effective date: 20150326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141220

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 674744

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141220

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20051220

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20161223

Year of fee payment: 12

Ref country code: GB

Payment date: 20161228

Year of fee payment: 12

Ref country code: CH

Payment date: 20161223

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20161222

Year of fee payment: 12

Ref country code: BE

Payment date: 20161222

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20180101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171220

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190228

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502005014422

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171220